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FASN NEGATIVELY REGULATES NF-kB/P65 EXPRESSION IN BREAST 
CANCER CELLS BY DISRUPTING ITS STABILITY 
 
 The overexpression of the multi-domain enzyme fatty acid synthase 
(FASN) has long been associated with poor clinical prognosis and treatment 
outcome in various cancers. Previous research in the Zhang lab has determined 
a role for FASN in mediating increases in non-homologous end-joining (NHEJ) 
DNA double-strand break repair activity allowing for increased cancer cell 
survival, and this mechanism was found to involve inhibition of NF-kB/p65. The 
mechanism responsible for the regulation of NF-kB/p65 by FASN in cancer cells, 
however, remains unknown. To this end, I was able to determine that FASN 
negatively regulates both the expression and activity of NF-kB/p65 in breast 
cancer cells, and that this effect was likely mediated by the 16-carbon saturated 
fatty acid palmitate, the end product of FASN catalytic activity. Specifically, FASN 
was found to negatively regulate p65 expression by disrupting its protein stability 
as a result of an increase in poly-ubiquitination of p65 protein and subsequent 
proteasomal degradation. Further, I found that the phosphorylation site Thr254 of 
p65 is involved in the regulation of p65 protein stability by FASN, in that mutation 
of this residue resulted in a disruption in p65 stability. Finally, I was able to 
determine that FASN likely inhibits the ability of the peptidyl-prolyl cis/trans 
isomerase Pin1 to assist in maintaining p65 stability, in that both siRNA 
ix 
knockdown and pharmacological inhibition of Pin1 resulted in a reduction of p65 
expression in FASN shRNA knockdown cells. The determination of this signaling 
mechanism serves to expand our understanding of the role of FASN in breast 
cancer cells and has the potential to assist in uncovering more effective ways to 
target the oncogenic FASN pathway to kill breast tumor cells and to overcome 
resistance to drug treatment. 
 
Tao Lu, Ph.D., Co-Chair 
 
Jian-Ting Zhang, Ph.D., Co-Chair 
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Chapter 1: Introduction 
 
1.1 Breast Cancer 
 
1.1.1 Overview 
 Expected to be diagnosed in nearly 270,000 women in 2019 and account 
for the deaths of almost 42,000 women, the earliest documentation of breast 
cancer dates back to about 3500 BC as a result of the ability of breast tumors to 
be discovered upon physical examination (Lukong 2017). Despite the advent of 
modern medicine and the progression of the practice of surgical resection, as 
well as the development of therapies for treatment, cancer remains the second 
leading cause of death in women behind heart disease, wherein only lung cancer 
is more deadly than breast cancer. 
 
1.1.2. Risk Factors and Prevention 
 A variety of potential risk factors are believed to be associated with the 
development of breast cancer. While men can develop breast cancer, women are 
exceedingly more likely to develop the disease. According to the American 
Cancer Society, men account for less than one percent of breast cancer 
diagnoses. Also, age is known to be a significant factor impacting the 
development of breast cancer in that fewer than five percent of women 
diagnosed with breast cancer in the U.S are younger than 40.  
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 Genetic factors are also known to play a role in the development of the 
disease in that a subset of breast cancers is believed to be hereditary. The most 
common mutations correlated with breast cancer development involve the DNA 
repair genes breast cancer type 1 susceptibility protein (BRCA1) and BRCA2, 
DNA repair associated protein (BRCA2). While the impact of BRCA mutations 
varies depending on the study, about 70% of women having a mutation in either 
gene are expected to develop breast cancer at some point in their lifetime 
(Kuchenbaecker et al. 2017). Further, other inherited mutations, though less 
common, can contribute to breast cancer development including ATM 
serine/threonine kinase (ATM), tumor protein 53 (TP53), and phosphatase and 
tensin homolog (PTEN). 
 Other risk factors for breast cancer include race (African American and 
Caucasian women are more likely to develop breast cancer than other races), 
family history of the disease, previous breast cancer diagnosis, as well as 
possessing dense breast tissue. Certain lifestyle factors including excessive 
alcohol consumption, obesity, as well as the use of hormone therapy after 
menopause are also believed to contribute to a risk of developing breast cancer. 
 
1.1.3. Development and Progression 
 Breast cancers arise from two main areas – the milk ducts of the breast 
that transport breast milk (ductal carcinoma) and the milk-producing lobules 
(lobular carcinoma). Despite this difference in origin, the progression of both 
ductal and lobular carcinoma is quite similar. Generally, the progression is 
3 
characterized by the growth and expansion of epithelial cells within the duct or 
lobule until the duct or lobule is consumed by the tumor cells, eventually resulting 
in intravasation of these cells out of the basement membrane to induce 
metastasis to distant organs including the bone, lymph nodes, lungs, liver, and 
the brain. This process is also accompanied by genetic changes, as well as 
increases in angiogenesis, increased proliferation of macrophages within the 
tumor stroma, and the proliferation of cancer-associated fibroblasts.   
 
1.1.4. Molecular Subtypes and Treatment Options 
 Breast cancer, relative even to other forms of cancer, exhibits a very high 
level of tumor heterogeneity. To this end, there are four main types of breast 
cancer, each possessing qualities that directly affect its ability to be treated 
effectively in the clinic. The molecular characteristics and associated treatment 
options for these subtypes are summarized in Table 1. The most common 
molecular subtype, accounting for about 70% of all breast cancers, is Luminal A 
breast cancer, which is also the most treatable form of breast cancer (Blows et 
al. 2010). Luminal A is characterized by the expression of hormone receptors 
(estrogen receptor (ER) and/or progesterone receptor (PR)) and the lack of 
expression of the human epidermal growth factor receptor 2 (HER2) receptor. As 
a result of this receptor expression, it possesses the most favorable prognosis of 
the subtypes and can often be effectively treated with targeted therapies such as 
tamoxifen and aromatase inhibitors (Haque et al. 2012). 
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 Similar to Luminal A, Luminal B breast cancer, accounting for about 12% 
of breast cancers, is characterized by the expression of ER and/or PR as well. 
However, these breast cancers possess a high percentage of Ki67 positive cells, 
indicating these tumor cells are rapidly proliferating, and also can be HER2 
positive (Blows et al. 2010). As a result of the highly proliferative nature of these 
cancers, though they can also be susceptible to hormone therapy, they exhibit 
poorer prognosis relative to Luminal A breast cancers. 
 Breast cancers that do not express ER or PR but do express HER2 are 
termed HER2 positive breast cancers and account for about 5% of all breast 
cancers (Haque et al. 2012). While HER2 type breast cancers are considered 
more aggressive than hormone receptor positive breast cancers and are 
associated with overall poorer prognosis, treatment outlook for patients with this 
subtype has improved with the development of HER2-targeted therapies such as 
trastuzumab (trade name Herceptin) (Perez et al. 2014; Goldhirsch et al. 2013; 
Pivot et al. 2013).  
 Finally, the most difficult subtype of breast cancer to treat is unequivocally 
triple-negative breast cancer (TNBC), which does not express any targetable 
receptors and makes up about 10-15% of all breast cancers (Haque et al. 2012). 
These cancers are almost always highly invasive forms of cancer, are lacking in 
distinctive histological characteristics, and can only be treated with 
chemotherapeutics and radiation, regardless of stage and advancement 
(Bianchini et al. 2016). Due to this detrimental combination of factors, TNBCs 
have the poorest prognosis of all breast cancer subtypes. Standard neoadjuvant 
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regimen for TNBC patients involves either anthracyclines, typically doxorubicin, 
or taxanes, typically docetaxel or paclitaxel. While about 30-40% of patients with 
early-stage TNBC will achieve remission on this standard neoadjuvant regimen 
(Minckwitz et al. 2012), nearly all patients with metastatic TNBC will ultimately 
succumb to their disease regardless of treatment regimen (Bonotto et al. 2014). 
As a result, while certain targeted therapies such as poly (ADP-ribose) 
polymerase (PARP) inhibitors and immune checkpoint inhibitors have shown 
some promise in clinical trials, TNBC remains largely untreatable and the search 
for effective options for treatment of these patients is ongoing. 
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Table 1. Breast cancer molecular subtypes and treatment options. 
A summary of the four main molecular subytpes of breast cancer and their  
prevalence of occurrence, along with descriptions of expression  
characteristics and available clinical treatment options. 
 
1.2. Fatty Acid Synthase (FASN) 
 
1.2.1. FASN Structure 
 FASN is a very large, enzymatic protein consisting of seven domains, six 
of which exhibit catalytic activity (Chirala and Wakil 2004). In order of their 
orientation from the N-terminus, these seven domains are b-ketoacyl synthase 
(KS), malonyl/acetyltransferase (MAT), b-hydroxyacyl dehydratase (DH), enoyl 
reductase (ER), b-ketoacyl reductase (KR), acyl carrier protein (ACP), and the 
culminating catalytic enzyme, thioesterase (TE) (Maier et al. 2008). The 
orientation of these seven domains is shown in Figure 1. A highly flexible 
structure exhibiting multiple conformational states allows for the protein to 
efficiently and effectively transport the growing fatty acid chain between domains. 
Molecular 
Subtype
Percentage of 
Breast 
Cancers
Characteristics Treatment Options
Luminal A 70%
ER+ and/or PR+
HER2-
Ki67 Low
Hormone therapies
(eg, tamoxifen, 
aromatase inhibitors)
Luminal B 12%
ER+ and/or PR+
HER2+/-
Ki67 High
Hormone therapies
(eg, tamoxifen, 
aromatase inhibitors)
HER2-Type 5%
ER-
PR-
HER2+
HER2-targeted therapies
(eg, Herceptin)
Triple-Negative 10-15%
ER-
PR-
HER2-
Neoadjuvant 
chemotherapy and 
radiation
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1.2.2. FASN Biosynthesis Pathway 
 The primary function of FASN is to utilize acetyl-CoA and malonyl-CoA to 
generate the 16-carbon saturated fatty acid palmitate as its enzymatic product 
(Figure 2). The initial step in this process involves the carboxylation of acetyl-
CoA to malonyl-CoA by acetyl-CoA carboxylase (ACC). Following this reaction, 
the growing fatty acid chain is elongated in seven sequential condensation 
reactions that add 2 additional carbons per reaction, wherein the nascent fatty 
acid is shuttled between enzymatic domains by ACP. This series of reactions 
culminates in the hydrolysis of the thioester linkage between the fatty acid chain 
and ACP by the TE domain and the release of the mature palmitate. The mature 
fatty acid is then transported throughout the cell where it is incorporated into a 
variety of higher order lipids which participate in a multitude of different cellular 
functions. 
 
 
Figure 1. Cartoon depiction of the orientation of domains within the 
FASN protein crystal structure.  
Within the protein crystal structure of FASN, there exists two distinct 
groupings of individual domains. The N-terminal grouping consists of 
the KS, MAT, and DH domains, which exhibit a dimeric structure, 
while the C-terminal grouping contains the ER, KR, ACP, and TE 
domains. The residues between these two domain groupings are 
termed the core region of the enzyme. These residues, while not 
enzymatic in nature, do exhibit secondary structure. Adapted from 
Maier et al. 2008. 
KS LD MAT DH DH’ ER KR ACP TE
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1.2.3. FASN and Cancer 
 In normal cells, the preferred pathway for energy production is aerobic 
respiration in the mitochondria, an efficient, high-yield process resulting in the 
production of 36 ATP. However, unlike normal cells, cancerous cells consume 
large quantities of glucose and preferentially utilize lactic acid fermentation for 
 
 
 
Figure 2. Mechanism of the fatty acid biosynthesis pathway.  
When the citric acid cycle intermediate citrate is in excess, it is shunted 
out of the cycle and is released from the mitochondria into the 
cytoplasm. Citrate is then converted to acetyl-CoA. Next, acetyl-CoA is 
carboxylated to malonyl-CoA by acetyl-CoA carboxylase. Malonyl-CoA, 
a two-carbon molecule, is then used in a series of seven consecutive 
condensation reactions, catalyzed by FASN and using NADPH as a 
reducing agent, which is supplied through the pentose phosphate 
pathway. From these reactions, the 16-carbon saturated fatty acid 
palmitate is synthesized and released in its mature form when it is 
hydrolyzed from the thioesterase domain. Palmitate is then incorporated 
into complex lipids including lipid signaling molecules, lipids used for 
energy production to meet cellular requirements via the fatty acid 
oxidation pathway, lipids used to post-translationally modify proteins, 
and for the membrane requirements of the cell. Adapted from Kuhajda 
2000.  
 
Mitochondria
CitrateCitric
Acid
Cycle
Glucose
Citrate
ATP Citrate 
Lyase
Acetyl-CoA
Malonyl-CoA
Acetyl-CoA
Carboxylase
Fatty 
Acid 
Synthase
Palmitate
Pentose
Phosphate
Pathway
NADPH
Lipids
Storage for Energy
Signaling Molecules
Post-translational Modifications
Membrane Production
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energy production, despite their substantial energy requirements as rapidly 
dividing cells. Uncovered by Otto Warburg, this paradoxical phenomenon is 
termed the Warburg effect (Warburg 1956). The goal of this process is to rapidly 
generate metabolic intermediates instead of ATP in order for these intermediates 
to be used to satisfy the cellular requirements of cancer cells as rapidly 
proliferating cells. 
 Following Warburg’s observations, it soon became clear that glucose 
metabolism was not the only metabolic abnormality exhibited by tumor cells. 
Specifically, while normal cells obtain the fatty acids necessary for their cellular 
requirements from dietary uptake, tumor cells undergo significant de novo fatty 
acid synthesis. Newly synthesized fatty acids have a variety of roles in cancer 
cells including utilization in membrane production to satisfy the substantial 
membrane requirements of rapidly dividing cancer cells, the production of higher 
order lipids to be stored for energy production through fatty acid b-oxidation, as 
well as the generation and modification of cellular signaling molecules. 
  Though this substantial increase in de novo fatty acid synthesis had been 
uncovered, a potential specific role for FASN in promoting cancer was not clear 
until the discovery of oncoantigen 519 (OA-519), which was subsequently 
identified as FASN, as a novel prognostic marker in prostate cancer (Epstein et 
al. 1995; Shurbaji et al. 1996). FASN was then found to also exhibit a role as a 
prognostic marker in breast cancer (Alo et al. 1996; Alo et al. 1999). Shortly 
thereafter, it was determined that FASN inhibition with cerulenin inhibited breast 
cancer cell growth and promoted breast cancer cell apoptosis, thereby indicating 
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a direct role for FASN in promoting the progression of cancer (Pizer et al. 1996). 
In subsequent years, studies determined this phenomenon to be consistent 
across many different types of cancer both in vitro and in in vivo xenograft tumor 
models, indicating a broader role for the involvement of FASN in tumor growth. 
 In addition to the role of FASN as a prognostic marker in cancer and the 
ability of FASN inhibition to suppress tumor growth, a role for FASN in promoting 
cancer drug resistance in breast cancer cells was determined (Liu et al. 2008). 
Specifically, FASN was significantly upregulated in drug resistant breast cancer 
cells, while knockdown of FASN level or inhibition of FASN pharmacologically 
reversed this drug resistance phenotype (Liu et al. 2008). Further supporting the 
contribution of FASN to drug resistance, FASN overexpression was also found to 
promote resistance to gemcitabine and radiation treatment in pancreatic cancer 
cells (Yang et al. 2011). As a result, FASN remains a potential therapeutic target 
for the treatment of a variety of different forms of cancer both as a potential 
adjuvant therapy, as well as to overcome acquired drug resistance to 
chemotherapeutic treatment. 
 
1.2.4. Lipid Signaling in Cancer 
 As referenced earlier, the substantial increases in de novo lipogenesis in 
cancer cells can have a profound effect on cell signaling pathways. One of the 
most common ways FASN can affect cell signaling is through the process of 
protein acylation, and one key example of protein acylation impacting cell 
signaling events in cancer settings lies with the Wnt protein family (Rohrig and 
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Schulze 2016). The Wnt proteins are modified by protein palmitoylation, 
characterized by the addition of a palmitoyl moiety to a cysteine residue, and this 
enzymatic process is mediated by an O-acyltransferase known as porcupine 
(PORCN) (Nile and Hannoush 2016). Palmitoylation is essential for the ability of 
the Wnt proteins to be secreted and subsequently bind to their target receptors 
on the cell membrane to activate the Wnt signaling pathway, and it has been 
shown that blocking the action of PORCN in this process can stop cancer cell 
growth in Wnt-driven cancers (Abrami et al. 2008; Komekado et al. 2007; Proffitt 
et al. 2013). Other proteins that are palmitoylated include the Ras small 
GTPases, and the palmitoylation of these proteins aids in Ras trafficking and 
enhances Ras signaling by promoting Ras association in signaling microdomains 
near the membrane (Eisenberg et al. 2013).  
 The increased fatty acid production in cancer cells can also lead to the 
increased generation of lipid molecules that participate directly in cancer 
signaling processes. Some of the signaling lipids that have roles in mediating 
cancer progression include sphingosine-1-phosphate (S1P) and lysophophatidic 
acid (LPA), as well as second messenger molecules, such as diacylglycerol 
(DAG) and phosphatidylinositiol-3,4,5-trisphosphate (PIP3) (Rohrig and Schulze 
2016). With the increases in de novo fatty acid synthesis that are seen in cancer 
cells, the consequence is an abundance of free fatty acids in the cell, which 
allows for the rapid remodeling and reprogramming of higher order lipids into 
these lipid signaling molecules, and these molecules are known to play roles in 
many cancer-promoting signaling pathways that contribute to increased cancer 
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cell survival, proliferation, and angiogenesis. Therefore, lipids contribute to 
cancer cell growth and survival both through the modification of proteins in the 
cell, as well as directly via lipid signaling molecules.   
 
1.3. Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells (NF-kB) 
 
1.3.1. NF-kB Signaling Pathway 
 The NF-kB signaling pathway is fairly complex in that it can be activated 
by a variety of different stimuli and has many points of regulation. However, a few 
major molecular players predominate in the NF-kB pathway. These molecular 
players include p50 and RelA/p65, two proteins that form a heterodimeric 
complex and constitute the DNA binding proteins responsible for the 
transcriptional activity of NF-kB; the nuclear factor of kappa light polypeptide 
gene enhancer in B cells inhibitor (IkB) proteins, most specifically IkBa, which 
constitute the inhibitory proteins of NF-kB within the cytosol; and the IkB kinase 
complex, consisting of IKKa, IKKb, and NF-kB essential modulator (NEMO), 
which participates in initiating the activation of the NF-kB pathway upon response 
to a stimulus (Gilmore 2006).  
 Canonically, upon the binding of a stimulus to a receptor, adaptor proteins 
recruit the IKK complex to the membrane. Activated IKK then phosphorylates the 
IkBa inhibitory subunit, inducing its poly-ubiquitination and proteasomal 
degradation, leaving p65/p50 free in the cytosol and allowing it to translocate to 
the nucleus and activate gene transcription (Figure 3). Due to the post-
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translational modifications within this pathway and the dependence of activation 
on the degradation of the inhibitory subunit, NF-kB signaling is transient in nature 
and also very tightly regulated.  
 Transcriptional activation of the NF-kB signaling pathway regulates the 
gene expression of over 150 target genes (Pahl 1999). These genes include 27 
different cytokines and chemokines, several immune receptors, genes involved in 
antigen presentation, cell adhesion molecules, apoptotic regulators, growth 
factors, stress response genes, transcription factors, many members of the NF-
kB signaling pathway itself, and many other genes (Pahl 1999). Because of the 
complex nature of the regulation of the NF-kB signaling pathway, specific 
subsets of these genes will be transcriptionally activated depending in large part 
on the stimulus present, as well as the cell type in which activation is occurring.   
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Figure 3. Canonical NF-kB signaling pathway. 
Canonically, upon the binding of a stimulus to a receptor, such as the 
interaction between tumor necrosis factor-alpha (TNF-a) and the tumor 
necrosis factor receptor (TNFR), the NF-kB intracellular signaling 
pathway is activated, wherein adaptor proteins are recruited to the 
stimulated receptor at the membrane. These adaptor proteins recruit 
and bind the IKK complex, which is activated upon the formation of the 
complex. Once activated, the catalytic subunits of the IKK complex, 
IKKa and IKKb, serve to phosphorylate the inhibitory subunit IkBa, 
which is bound to the p65/p50 heterodimer in the cytosol, at Ser32 and 
Ser36, leading to the poly-ubiquitination and proteasomal degradation of 
IkBa. The degradation of IkBa leaves the p65/p50 heterodimer free in 
the cytosol, thereby allowing for its nuclear translocation, wherein it 
binds to consensus binding elements present in target gene promoters 
and participates in the activation of gene transcription. Adapted from 
Jost and Ruland 2007. 
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1.3.2. NF-kB Signaling Function and Role in Cancer 
 The transcriptional activity of NF-kB plays an important functional role in 
both inflammation and cancer, and these pathological roles are also intertwined 
in that many genes regulated by NF-kB contribute to both pathologies. In normal 
conditions, the induction of NF-kB’s pro-inflammatory gene expression 
programming results in an effective response to insult or injury within the human 
body that can be resolved in a timely manner (Zhang and Sun 2015; Lawrence 
2009). However, dysregulation of this immune response, often involving 
constitutive activation of NF-kB, can lead to chronic inflammation and 
pathological immune-related disorders.  
 The relationship between NF-kB and cancer is multi-faceted. The most 
well-documented role of NF-kB signaling in cancer involves constitutive NF-kB 
activation and, specifically, the ability of NF-kB to regulate a myriad of genes that 
control cell proliferation, as well as apoptosis and cell survival. A long history of 
evidence suggests that the regulation of pro-proliferation genes and anti-
apoptotic genes goes hand-in-hand to promote tumorigenesis, and there is 
evidence to suggest that inhibiting the activity of NF-kB can reverse the 
tumorigenic phenotype resulting from constitutive NF-kB activation and trigger 
apoptosis (Biswas et al. 2003; Karin and Lin 2002; Barkett and Gilmore 1999; 
Biswas et al. 2004).  
 The NF-kB gene expression profile responsible for tumor promotion is 
also believed to involve genes involved in the promotion of angiogenesis and 
metastasis. While the relationship between NF-kB and promotion of invasiveness 
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is not as well-studied as its dual role in prevention of apoptosis and promotion of 
proliferation, it has been shown that the NF-kB target gene interleukin-8 (IL-8) 
contributes to angiogenesis (Koch et al. 1992). Further, it has also been shown 
that inhibiting NF-kB resulted in a decrease in angiogenesis and tumor growth, 
as well as increased survival in mice, and was accompanied by reduced 
expression of both IL-8 and another angiogenic gene, vascular endothelial 
growth factor (VEGF) (Huang et al. 2000).  
 Further, aside from the somewhat general roles NF-kB signaling plays in 
the progression of a variety of tumor types, NF-kB signaling plays a specific role 
in the development of leukemias and lymphomas (Karin et al. 2002). For 
instance, for a specific subtype of diffuse large B-cell lymphoma (DLBCL), 
constitutive activation of NF-kB is, in fact, required for cancer cell viability (Bidere 
et al. 2009). Also, certain germline mutations in NF-kB are particularly prevalent 
in certain leukemias and lymphomas resulting in a unique reliance of the cancer 
on NF-kB or a predisposition to the development of the cancer (Leeksma et al. 
2017). 
 In breast cancer, NF-kB has been shown to upregulate genes implicated 
in cancer progression, including cyclin D1, cyclin-dependent kinase 2, and c-Myc 
(Wang et al. 2015). NF-kB activation in breast cancer has also been specifically 
linked to the upregulation of cytokines, as well as anti-apoptotic and pro-survival 
genes. Interestingly, a link has been determined between NF-kB activation and 
HER2-type breast cancer, wherein HER2 overexpression leads to an 
upregulation of NF-kB activity resulting in increased cancer cell proliferation 
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(Merkhofer et al. 2010). Another study also determined that constitutive NF-kB 
activation led to the development of drug resistance in HER2-overexpressing 
breast cancer cells (Bailey et al. 2014).  
 It is also believed that NF-kB activation plays a particular role in breast 
cancer by interacting with tumor stroma and cancer stem cells to promote 
epithelial-mesenchymal transition and metastasis. To this end, NF-kB signaling is 
known to lead to the upregulation of a variety of genes in breast cancers involved 
in the promotion of metastasis, and this process is believed to involve the ability 
of pro-inflammatory signaling from the tumor microenvironment to translate to 
NF-kB-mediated gene expression changes (Wang et al. 2015).  
 Aside from the role of NF-kB in promoting drug resistance in HER2-type 
breast cancer, it is also believed NF-kB activation may contribute to the 
development of resistance to endocrine therapies such as tamoxifen, wherein 
crosstalk between constitutive NF-kB signaling activation and ER signaling acts 
to promote ER activity (Khongthong et al. 2019). Additionally, as might be 
expected, breast cancer cell treatment with chemotherapeutic agents including 
doxorubicin and taxanes such as paclitaxel has been shown to induce NF-kB 
activation to promote treatment resistance through the upregulation of pro-
survival genes (Tergaonkar et al. 2003; Esparza-Lopez et al. 2013; Patel et al. 
2000).  
 Interestingly, within cancer settings, NF-kB does not always participate in 
tumor promotion and prevention of cell death. In some cases, it has been shown 
that the activation of NF-kB can actually promote cell death. Specifically, it has 
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been shown that stimulation of NF-kB by interleukin 1 (IL-1) in co-stimulated 
epithelial carcinoma KB cells and keratinocytes resulted in increases in both 
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced 
apoptosis (Kothny-Wilkes et al. 1998), as well as UVB radiation-induced 
apoptosis (Strozyk et al. 2006). Also, another study showed that disruption of NF-
kB signaling by either inhibiting NF-kB with pyrrolidine dithiocarbamate (PDTC) 
or by transfection of mutant IkBa to prevent RelA/p65 nuclear translocation 
resulted in decreased sensitivity of neuroblastoma cells to doxorubicin treatment, 
again suggesting NF-kB can play a positive role in cell death mechanisms (Bian 
et al. 2001). Further, transfection of an antisense IkBa vector to reduce IkBa 
expression, thereby inducing increased NF-kB activation, resulted in increased 
sensitivity of breast cancer cells to paclitaxel-induced cell death (Huang and 
Johnson et al. 2000). While these examples of NF-kB acting to promote cell 
death and apoptosis may appear isolated, there is cell signaling evidence 
supporting this role for NF-kB, in that DNA-damaging agents have been shown to 
lead to NF-kB-mediated upregulation of Fas ligand, a common activator of 
extrinsic apoptotic pathways, thereby suggesting further that the role of NF-kB 
signaling in response to chemotherapeutic treatment may be complex 
(Kasibhatla et al. 1998). 
 
1.3.3. Stimulation of NF-kB by TNF-a  
 TNF-a is a cytokine known to play a dual role in cancer in that it can act in 
both a pro-survival and pro-apoptotic manner. With regard to the activation of 
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NF-kB, however, TNF-a is known to bind to the TNF receptor to stimulate the 
canonical NF-kB signaling pathway through the activation of the IKK complex. 
Canonical activation of NF-kB signaling by the binding of TNF-a to its receptor 
leads to a transcriptional response that can upregulate a variety of genes 
including pro-inflammatory cytokines, as well as a variety of genes involved in 
anti-apoptotic mechanisms (Zhou et al. 2003). The potential role for TNF-a in 
promoting apoptosis and cell death through NF-kB is unclear, but it has been 
shown that combined stimulation of colon cancer cells with TNF-a and interferon-
alpha (IFN-a) resulted in increased apoptosis mediated by NF-kB-driven 
upregulation of Fas ligand (Kimura et al. 2003). TNF-a is not directly linked to 
activation of the noncanonical NF-kB pathway; however, there are several TNF 
family members that can regulate the noncanonical pathway, including CD40 
ligand, which acts to induce activation of p52/RelB heterodimer-mediated 
transcription (Hayden and Ghosh 2014).  
 
1.3.4. Regulation of NF-kB/p65 
 As discussed earlier, NF-kB signaling activation is very tightly regulated. 
While the most prominent regulatory action in the NF-kB signaling pathway 
involves the phosphorylation and subsequent degradation of the inhibitory 
subunit IkBa, NF-kB signaling can also be regulated by direct modification of the 
NF-kB proteins.  
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 Specifically, phosphorylation of the NF-kB proteins has been found to play 
a major role in regulating the NF-kB signaling pathway. Phosphorylation of the 
NF-kB proteins at a variety of different sites controls transcriptional activation, 
protein-protein interactions, and protein stability (Christian et al. 2016). Many of 
these phosphorylation events occur on the NF-kB subunit p65 leading to a 
multitude of different effects both on p65 itself and within the cell. In fact, 11 such 
sites of p65 phosphorylation have been identified (Christian et al. 2016). A full list 
of these phosphorylation sites and their corresponding effects is displayed in 
Table 2. 
 Perhaps the most well-studied of these phosphorylation sites is Ser536, 
which is located in the transactivation domain of the protein. A number of kinases 
have been identified to phosphorylate Ser536, including IKKa, IKKb, and IKKe, 
among others (Buss et al. 2004; Lawrence et al. 2005; Sakurai et al. 1999; 
Sizemore et al. 2002). One well characterized consequence of p65 Ser536 
phosphorylation is the binding of the acetyltransferase CREB-binding 
protein/p300 (CBP/P300), resulting in increased acetylation of p65 at Lys310, 
and subsequently resulting in increased NF-kB transactivation (Chen et al. 
2005). The effects of p65 Ser536 phosphorylation on NF-kB transcriptional 
activity have been described in many additional studies, and it is the p65 site 
most commonly associated with NF-kB activation. 
 Another well-characterized p65 phosphorylation site is Ser276. The main 
kinase involved in Ser276 phosphorylation is Protein Kinase A (PKA), and PKA 
phosphorylation of Ser276, similar to Ser536 phosphorylation, promotes the 
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interaction of p65 with CBP/P300 and results in p65 transcriptional activation 
(Zhong et al. 1998). Another kinase that has been shown to phosphorylate 
Ser276 is proto-oncogene serine/threonine-protein kinase (Pim-1) (Nihira et al. 
2010). Phosphorylation of p65 at Ser276 by Pim-1 was found to not only 
enhance p65 transcriptional activity, but also prevent the poly-ubiquitination and 
proteasomal degradation of p65, thereby resulting in increased p65 protein half-
life (Nihira et al. 2010).  
 Further, another phosphorylation site that has been found to be implicated 
in NF-kB activation, for which the responsible kinase is still yet unknown, is 
Thr254 (Xing et al. 2011; Ryo et al. 2003). Similar to the Ser276 site, when 
Thr254 of p65 was mutated, p65 protein stability was significantly reduced, as 
was the ability for p65 to translocate to the nucleus in the presence of a stimulus 
or activate a luciferase reporter (Ryo et al. 2003). However, mutation of a 
different residue also known to be involved in NF-kB activation, Ser316, did not 
affect p65 protein stability, indicating that Ser316 regulates NF-kB activation 
through a different mechanism. Further, inhibition of proteasomal degradation 
with the inhibitor MG132 resulted in a rescue of p65 protein following mutation of 
Thr254, indicating that disruption of p65 protein stability will induce its 
degradation through the proteasome. Immunoprecipitation studies showed that 
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (Pin1) was able to bind to 
p65, but that binding was disrupted upon Thr254 mutation, indicating that Pin1 
preferentially binds to the phospho-Thr/Pro motif present at residues 254 and 
255 in the p65 amino acid sequence. It was also found that loss of Pin1 resulted 
22 
in a reduction in NF-kB activity, p65 nuclear translocation, and p65 protein 
stability, suggesting that Pin1 is essential to p65 stability and, subsequently, NF-
kB activity. Therefore, phosphorylation of many sites on the NF-kB subunit p65 
tightly regulate both the transcriptional activity of NF-kB and the protein stability 
of p65.  
  
 
Table 2. Identified p65 phosphorylation sites, responsible kinases, and the 
functional outcomes of the phosphorylation events. Reprinted here with 
permission from Christian et al. 2016 under the Creative Commons Attribution 
License. 
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 The termination of the NF-kB signaling response is also very tightly 
regulated and primarily occurs through feedback loops. These feedback loops 
are controlled by gene transcription and protein modification. For example, 
following NF-kB activation by TNF-a stimulation, the inhibitory protein IkBa is re-
synthesized through NF-kB’s transcriptional activity. The newly synthesized IkBa 
proteins then enter the nucleus and remove NF-kB proteins from their target 
gene promoters, resulting in the termination of gene transcription (Zabel and 
Baeuerle 1990). Further, proteasomal degradation can aid in the termination of 
the NF-kB signaling response. Ubiquitination of the p65 subunit of NF-kB can be 
mediated by several E3 ubiquitin ligases, including suppressor of cytokine 
signaling (SOCS-1) and PDZ and LIM domain (PDLIM2) (Renner and Schmitz 
2009). Conjugation of ubiquitin to p65 by these E3 ligases subsequently results 
in the proteasomal degradation of p65 and the termination of the transcriptional 
response.  
 
1.4. Peptidyl-Prolyl Cis/Trans Isomerase NIMA-Interacting 1 (Pin1) 
 
1.4.1. Overview of Pin1 Function 
 Peptidyl-prolyl isomerases are a group of enzymes that affect protein 
folding and conformations by catalyzing the cis/trans isomerization of the peptide 
bonds of proline residues. As a result of the ability of the peptidyl-prolyl 
isomerases to affect the conformations of many proteins, their activity is linked to 
a variety of different cellular effects.  
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 Pin1 is a specific isomerase that catalyzes the isomerization of proteins at 
phosphorylated-serine/threonine-proline motifs (Zhou et al. 1999). Because of 
this targeted enzymatic activity, Pin1 is known to play specific signaling roles in 
cells throughout the body to impact different disease states, including 
neurological diseases such as Alzheimer’s disease, Huntington’s disease, and 
Parkinson’s disease, as well as a variety of cancers (Chen et al. 2018).  
 
1.4.2. The Role of Pin1 in Breast Cancer 
 In cancers, Pin1 is often found to be overexpressed and its 
overexpression or overactivation is known to be correlated with a poor clinical 
prognosis (Driver et al. 2012; Driver et al. 2015). Specifically, with respect to 
breast cancer, a study found that Pin1 expression was about tenfold increased in 
breast tumors compared to normal tissues, and that Pin1 expression increased in 
proportion to increases in invasiveness of breast tumors (Wulf et al. 2001).  
 Pin1 is known to regulate a variety of genes and processes in breast 
cancer cells, including regulating proliferation both by interacting with ERa to 
promote ER signaling and by promoting the stability of HER2 (Rajbhandari et al. 
2012; Lam et al. 2008). Pin1 is also believed to play a role in invasion and 
metastasis in breast cancer, in that Pin1 has been shown to increase activation 
of both the Notch signaling pathway and the signal transducer and activator of 
transcription 3 (STAT3) signaling pathway (Rustighi et al. 2009; Lufei et al. 
2007). As stated earlier, Pin1 has been linked to stability of NF-kB through 
binding to the phosphorylated-Thr254-Pro motif of p65 and has also been linked 
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to other pro-survival mechanisms, including the promotion of resistance to 
tamoxifen treatment in ER+ breast cancer cells (Ryo et al. 2003; Namgoong et al. 
2010). 
 
1.5. Established Relationship Between FASN and NF-kB 
 
1.5.1. FASN Regulates DNA Repair Activity via NF-kB Signaling 
 Concurrent with the uncovered relationship between FASN and drug 
resistance, it was also recently discovered that FASN overexpression results in 
resistance to a variety of different DNA-damaging agents, including doxorubicin, 
mitoxantrone, etoposide, and cisplatin, suggesting a relationship wherein FASN 
may desensitize cancer cells to DNA damage (Liu et al. 2013). When 
investigating potential signaling pathways that could be involved in this 
relationship, an array analysis showed that only two genes, both involved in the 
regulation of NF-kB, out of nearly 100 that were tested were significantly 
affected—TNF-a and IL-8, wherein the expression of both genes was 
significantly reduced with FASN overexpression in MCF7 breast cancer cells (Liu 
et al. 2013). This negative correlation between FASN and TNF-a expression held 
true both in the presence and absence of doxorubicin treatment to induce DNA 
damage. Further, it was also found that FASN overexpression in MCF7 cells 
decreased p65 protein level, while FASN knockdown, also in MCF7 cells, 
resulted in an increase in NF-kB activity (Liu et al. 2013). These findings 
indicated a potential relationship between FASN and NF-kB, wherein FASN may 
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prevent cancer cell death resulting from DNA damage involving inhibition of NF-
kB signaling through TNF-a. This phenomenon would be consistent with the non-
canonical functional outcome of NF-kB signaling described earlier, wherein NF-
kB may actually promote rather than prevent tumor cell death.  
 Further study indicated a specific role for NF-kB in the relationship 
between FASN and DNA repair. FASN was found to be able to upregulate the 
repair of DNA double-strand breaks by increasing non-homologous end-joining 
(NHEJ) DNA repair activity, and this was accomplished through increasing the 
expression and activity of poly (ADP-ribose) polymerase 1 (PARP1) (Wu et al. 
2016) (Figure 4). Interestingly, the expression of PARP1 was found to be 
regulated by a composite transcription factor binding site between specificity 
protein 1 (SP1) and NF-kB (Wu et al. 2016). As a result, FASN increased the 
expression of SP1, while decreasing the expression of NF-kB/p65 to allow for the 
increases in expression and activity of PARP1. Supporting the proposed 
relationship between NF-kB and PARP1, overexpression of p65 suppressed 
PARP1 expression (Wu et al. 2016). Similarly, treating cells with TNF-a to 
activate NF-kB also reduced PARP1 expression. Finally, knockdown of p65 
resulted in an increase in NHEJ DNA repair activity, ultimately indicating that 
FASN inhibits NF-kB, which relieves an ability of NF-kB, through an unknown 
mechanism, to reduce PARP1 expression, thereby preventing the activation of 
the DNA repair process. 
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Figure 4. Mechanism of FASN regulation of NHEJ DNA repair.  
When FASN expression is high in breast cancer cells, FASN 
induces an increase in SP1 expression, while concurrently 
suppressing NF-kB/p65 expression. This relieves NF-kB’s ability 
to inhibit PARP1 and allows SP1 to upregulate the expression 
and activity of PARP1. PARP1 then carries out its poly (ADP) 
ribosylation activity on various target proteins, including 
Ku70/Ku80 protein dimers, allowing for the retention of 
Ku70/Ku80 at DNA double-strand break sites. Other proteins 
involved in DNA repair are also recruited, and NHEJ DNA repair 
is carried out to repair DNA breaks and allow for the continued 
survival of breast cancer cells in the presence of 
chemotherapeutic treatment with doxorubicin and other DNA-
damaging agents. Adapted from Wu et al. 2016. 
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 Other studies have also investigated potential links between FASN and 
NF-kB signaling. It has been found that pharmacological inhibition of FASN 
results in rapid translocation of p65 to the nucleus in SK-Br-3 breast cancer cells 
(Menendez et al. 2004) and in both A549 and H1975 lung cancer cells (Lemmon 
et al. 2011). Further, FASN inhibition also led to increases in NF-kB reporter 
activity, as well as the expression of NF-kB target genes (Lemmon et al. 2011). 
In this mechanism, NF-kB activation was dependent on protein kinase C (PKC) 
activation, which resulted in the PKC-mediated phosphorylation of the inhibitory 
subunit IkBa to lead to NF-kB activation in response to FASN inhibition with C93, 
a derivative of another inhibitor known as cerulenin (Lemmon et al. 2011). 
Therefore, there exists a clear relationship between FASN signaling and NF-kB 
signaling within different cancer settings, both in the presence and absence of 
chemotherapeutic treatment and DNA damage. 
 
1.6. Summary and Hypothesis 
 FASN is a metabolic enzyme that has been long characterized as having 
an important role in the progression of many forms of cancer, as well as being a 
negative indicator of disease prognosis and treatment outcomes. Previous 
research has uncovered a specific mechanistic role for FASN in breast cancer 
cells, wherein upregulation of FASN leads to increases in NHEJ DNA repair 
activity and, subsequently, increased breast cancer cell survival in the presence 
of DNA-damaging agents such as doxorubicin. While the ability of FASN to 
positively regulate NHEJ DNA repair activity in breast cancer cells has been 
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shown to involve the inhibition of NF-kB/p65, it remained unknown until now how 
FASN is able to regulate NF-kB to allow for FASN to exert this effect.  
 As a result, the goal of the study explored in this thesis was to investigate 
the mechanism behind FASN regulation of NF-kB/p65 in breast cancer cells. To 
this end, I hypothesized that FASN negatively regulates NF-kB/p65 expression in 
breast cancer cells by disrupting p65 protein stability. Data presented in this 
thesis will be shown to support that FASN negatively regulates p65 at the protein 
level but does not affect p65 transcription. Further, data will also demonstrate 
that, when FASN expression is high in breast cancer cells, p65 stability is 
decreased, while the inhibition of proteasomal degradation can reverse the ability 
of FASN to reduce p65 expression. Finally, this thesis will also show that the 
effect of FASN on p65 protein stability is likely due to reduced phosphorylation of 
p65 at Thr254 involving the activity of the prolyl isomerase Pin1. 
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Chapter 2: Materials and Methods 
 
2.1. Cell Lines and Culture Conditions 
 Human breast cancer cell lines MDA-MB-468 and MDA-MB-231 were 
cultured at 37 degrees Celsius with 5% (vol/vol) CO2 in DMEM (Thermo Fisher) 
supplemented with 10% (vol/vol) FBS. Drug-resistant MCF7 breast cancer cells 
(M3K) were generated previously (Chen et al. 1990) and were cultured in DMEM 
supplemented with 10% (vol/vol) FBS, 3000 ng/mL Adriamycin, and 5 µg/mL 
verapamil, which is used to prevent the overexpression of P-glycoprotein as a 
mechanism for Adriamycin resistance in this cells. The mechanisms of drug 
resistance that have been uncovered in this cell line since its initial selection are 
summarized in Table 3. Stable FASN-overexpressing MCF7 cells (MCF7/FASN) 
and its corresponding vector-transfected control cell (MCF7/Vec), as well as 
stable M3K cells with FASN knockdown (M3K/shFASN) and its scrambled 
shRNA-transfected control cell (M3K/shScr) were generated previously (Liu et al. 
2008), and were maintained in DMEM supplemented with 10% (vol/vol) FBS and 
400 µg/mL G418.  
 To generate stable clones in MDA-MB-436 cells with FASN 
overexpression, pcDNA(3.1) containing cDNA encoding human FASN (Liu et al. 
2008) was transfected into MDA-MB-436 cells using Metafectene Pro (Biontex). 
Two days after transfection, cells were re-plated at a 1:10 dilution, allowed to 
recover for 24 hours, and selected in the presence of 600 µg/mL G418 for a 
period of 2 weeks. Following selection, individual clones were propagated for 
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continued analysis. FASN overexpression was verified by Western blot. Cultured 
MDA-MB-436 cells with FASN overexpression (436/FASN) were subsequently 
maintained in MEM, 1X (Thermo Fisher) supplemented with 10% (vol/vol) FBS 
and 300 µg/mL G418.  
 
Resistance 
Mechanism 
Resistance 
Category 
Associated 
References 
Unknown 95 kDa 
membrane protein 
Drug efflux 
(unconfirmed) 
Chen et al. 1990 
BCRP/ABCG2 Drug efflux 
Litman et al. 2000; Doyle 
et al. 1998 
Other ABC Transporters Drug Efflux Liu et al. 2005 
14-3-3σ Cell cycle/DNA repair Liu et al. 2006 
FASN DNA repair 
Liu et al. 2008; Liu et al. 
2013; Wu et al. 2016 
Table 3. Summary of observed drug resistance mechanisms in M3K 
(MCF/AdVp3000) breast cancer cells. 
 
 
2.2. Western Blotting 
 Cultured cells were scraped and pelleted in sterile 1X PBS via 
centrifugation at 5,000xg for 5 mins. Pelleted cells were then washed once in 
sterile 1X PBS by centrifugation at 13,000 rpm for 10 mins. Cells were 
subsequently frozen at -80 degrees Celsius. Upon thawing, cells were lysed in 
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TNN lysis buffer [50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% NP-40, 1 mM 
EDTA, 0.1% SDS, 0.5 mM PMSF, 70 mM DTT] using intermittent vortexing and 
incubation of cells on ice. Cells were then sonicated three times for 15 seconds, 
followed by centrifugation at 13,000 rpm for 10 mins at 4 degrees Celsius to 
pellet cell debris. Supernatant was transferred to new tubes. Protein 
concentration was measured using a spectrophotometer (Bio-Rad) by Bradford 
assay using Bio-Rad protein assay dye. Samples containing equal protein 
concentration were then mixed with equal volume 2X SDS Sample Loading 
Buffer [200 mM Tris-HCl pH 6.8, 20% glycerol, 4% (w/v) SDS, 0.1% 
Bromophenol blue, 200 mM b-Mercaptoethanol]. Samples were then boiled for 
10 mins at 95 degrees Celsius and spun briefly at 13,000 rpm. Samples were 
then loaded onto SDS-PAGE gel and subsequently transferred to PVDF 
membrane overnight at 4 degrees Celsius. Membranes were blocked in 5% 
evaporated milk dissolved in 1X TBST, and immunoblotting was performed as 
previously described (Zhang et al. 1996; Yang et al. 2002) using primary 
antibodies against FASN (1:1000) (BD Biosciences; 610962), p65 (1:300) (Santa 
Cruz; sc-8008), PARP1 (1:1000) (Cell Signaling; 9542), P-p65-Ser536 (1:1000) 
(Cell Signaling; 93H1), b-Actin (1:5000) (Sigma; A5316), M2-FLAG (1:1000) 
(Sigma; F1804), Pin1 (1:1000) (Cell Signaling; 3722), and ubiquitin (1:1000) (Cell 
Signaling; 3933). Images were developed using ECL Western Blotting Detection 
Reagent (GE Healthcare) on X-Ray film. Images were quantified using ImageJ 
software.  
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2.3. Real-Time RT-PCR Analysis 
 Quantitative real-time PCR analysis was performed as described 
previously (Dong et al. 2005; Liu et al. 2013). Briefly, cells were cultured in 6-well 
plates for 48 hours if no drug treatment or 72 hours with drug treatment, wherein 
RNA was isolated from cell lysate using PureLink RNA Mini Kit (Invitrogen). RNA 
concentration was measured using a NanoDrop spectrophotometer. RNA was 
reverse-transcribed to cDNA using equal amounts of RNA for each sample with 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) followed by 
utilization of cDNA for real-time RT-PCR analysis with SYBR Green PCR Mix 
(Applied Biosystems) using a Step One Plus 7500 Real-Time PCR System 
(Applied Biosystems). CT values for target genes were normalized to a 
housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
Calculations were performed using the comparative CT method (Schmittgen and 
Livak 2008). Fold changes between groups were calculated by first normalizing 
CT values of target genes to GAPDH CT values indicating DCT values for each 
sample. Next, the calculation 2-DCT was performed, and the results of that 
calculation were used directly to determine fold change between treatment 
groups or genetic manipulations. Primer sequences utilized for target genes p65 
and TNF-a are listed in Table 4. 
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Table 4. Real-time RT-PCR primer sequences.  
List of real-time RT-PCR primer sequences for various gene targets investigated 
in this thesis. 
 
 
2.4. NF-kB Cis-reporter Activity Assay 
 NF-kB cis-reporter assay was performed according to the manufacturer’s 
instructions utilizing the Path Detect cis-reporting system (Agilent) as described 
previously (Wu et al. 2016). Briefly, cells were cultured overnight, followed by 
transfection with pNF-kB cis-reporter plasmid along with co-transfection of pRL-
TK renilla luciferase plasmid as an internal control for transfection efficiency 
using Metafectene Pro Reagent (Biontex). An empty vector excluding the NF-kB 
reporter elements was also transfected as a negative control for reporter activity. 
At 48 hours following transfection, cells were harvested and Dual-Luciferase 
Assay System (Promega) was performed. NF-kB activity was measured using 
Firefly luciferase measurement and was normalized to renilla luciferase values to 
account for transfection efficiency. 
 
2.5. 35S-Methionine Pulse-Chase Assay 
 To pulse-label cells, M3K/shFASN and M3K/shScr control cells were 
cultured to 75% confluence, then subsequently cultured in methionine-free 
Gene Target Sequence
GAPDH Forward AAGGACTCATGACCACAGTCCAT
GAPDH Reverse CCATCACGCCACAGTTTCC
p65 Forward TCTCCCTGGTCACCAAGGAC
p65 Reverse TCATAGAAGCCATCCCGGC
TNF-α Forward CCCAGGCAGTCAGATCATCTTC
TNF-α Reverse GGTTTGCTACAACATGGGCTACA
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DMEM medium supplemented with 10 µCi/mL 35S-Methionine for 2 hours 
allowing for radiolabeled methionine amino acid incorporation into newly 
synthesized peptides. 35S-Methionine was then washed out from the culture 
medium, and cells were cultured in complete DMEM for a chase period of 0-32 
hours, wherein cells were harvested at 8 hour intervals and stored at -80 degrees 
Celsius for later assay. Cell pellets were lysed in TNN lysis buffer, and protein 
concentration was measured as described above in section 2.2. 400 µg total 
protein was then used to immunoprecipitate p65 from total cell protein using an 
anti-p65 monoclonal antibody (Santa Cruz) and Protein G PLUS-Agarose beads 
(Santa Cruz). Beads were then washed in lysis buffer to remove off-target 
proteins. Proteins were eluted from beads by boiling in 2X SDS sample loading 
buffer, and SDS-PAGE was performed. Gels were dried using a vacuum system 
gel dryer and exposed to X-Ray film followed by quantification of radioactivity 
using scintillation counting. Curves for protein degradation were generated using 
GraphPad Prism 7 to obtain protein half-life measurements based on an average 
of three independent experiments by curve-fitting using one-phase exponential 
decay. 
 
2.6. siRNA Transfection 
 Cells were plated in 6-well plates and cultured for 24 hours. Cells were 
then transfected using scrambled control siRNA (Cell Signaling) or siRNA against 
Pin1 (Santa Cruz) in Opti-MEM reduced serum media (Thermo Fisher) using 
Lipofectamine RNAiMAX reagent (Thermo Fisher) according to the 
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manufacturer’s instructions. 48 hours following transfection, cells were harvested, 
and cell pellets were stored at -80 degrees Celsius for later assay. Western blot 
analysis was subsequently performed to verify siRNA knockdown and determine 
effects on total p65 protein level. 
 
2.7. Cycloheximide Chase Assay 
 Cells were plated in 6-well plates and cultured for 24 hours to reach 70% 
confluence. Cells were then transfected following 24 hour cell growth with either 
pcDNA(3.1) empty vector (negative control), pcDNA(3.1)-p65-FLAG, or 
pcDNA(3.1)-p65-T254A-FLAG in Opti-MEM reduced serum media using 
Lipofectamine 3000 Reagent (Thermo Fisher) according to the manufacturer’s 
instructions. WT pcDNA(3.1)-p65-FLAG was generously provided by Dr. Tao Lu, 
and T254A pcDNA(3.1)-p65-FLAG was generated using site-directed 
mutagenesis with pcDNA(3.1)-p65-FLAG being utilized as a template. 24 hours 
following transfection, cells were treated with 60 µg/mL cycloheximide (Sigma) in 
full serum DMEM media. Cells were then incubated at 37 degrees Celsius for a 
period of 0 to 12 hours and harvested at the indicated time points. Cell pellets 
were then stored at -80 degrees Celsius, and Western blot analysis was 
subsequently performed.   
 
2.8. Ubiquitination Assay 
 Cells were plated in 6-well plates and cultured for 24 hours to reach 70% 
confluence. After 24 hours, cells were transfected with WT pcDNA(3.1)-p65-
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FLAG using Opti-MEM reduced serum media and Lipofectamine 3000 
transfection reagent (Thermo Fisher) according to the manufacturer’s 
instructions. 24 hours following transfection, cells were treated with 2 µM MG132 
for a period of 4 hours. Following 4 hours proteasome inhibition, cells were 
harvested, cell pellets were spun down at 13,000 rpm for 10 minutes at 4 
degrees Celsius and stored at -80 degrees Celsius. Cells were subsequently 
lysed as described earlier in section 2.2 in TNN lysis buffer with intermittent 
vortexing and incubation on ice. Protein concentration was measured using 
Bradford assay, 50-100 µg total protein was added equally for paired isogenic 
cell lines to a microcentrifuge tube, and tube volume was adjusted to 500 µL 
using TNN buffer. Normal mouse IgG (Santa Cruz) was utilized to pre-clear 
protein lysates. Soluble protein was then transferred to new microcentrifuge 
tubes, and 1.5 µg of M2-FLAG antibody (Sigma) was then added to each tube, 
wherein tubes were placed on a rotator at 4 degrees Celsius for a period of 3 
hours to immunoprecipitate p65-FLAG from total protein lysate. After 3 hours 
immunoprecipitation, 40 µL Protein G-PLUS Agarose beads (Santa Cruz) was 
added to each tube, and tubes were placed on a rotator at 4 degrees Celsius 
overnight to conjugate bound p65-FLAG to the beads. Beads were subsequently 
spun at 5,000xg for 1 minute at 4 degrees Celsius and washed 5 times with TNN 
buffer containing 1 mM PMSF and 1 mM DTT to remove unbound and off-target 
proteins. Remaining TNN buffer was removed following the final wash, and 
proteins were eluted by addition of 2X SDS Sample Loading Buffer and boiling at 
95 degrees Celsius for 10 minutes. Beads were spun at 13,000 rpm for 3 minutes 
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to pellet the beads. Eluted proteins were loaded onto an SDS-PAGE gel. 
Following SDS-PAGE electrophoresis, gels were transferred to PVDF 
membranes (Bio-Rad) overnight at 4 degrees Celsius. Membranes were probed 
using a ubiquitin antibody (Cell Signaling) and exposed to X-Ray film. Western 
blot analysis was also performed in tandem using input controls to account for 
similar loading in the immunoprecipitation steps from total protein lysate. Input 
control blots were probed using antibodies for total p65 (Santa Cruz) and b-Actin 
(Cell Signaling).   
 
2.9. Cell Viability Assay 
 Cell viability was measured using the methylene blue cell staining assay. 
Cells were plated in 96-well plates at 2x104 cells per well and cultured for 24 
hours. Media was changed containing cerulenin at varying concentrations using 
serial dilution or vehicle, and cells were treated for 72 hours. After 72 hour 
treatment, cells were fixed in 100% methanol for 30 mins at room temperature. 
After fixing, methanol was aspirated from cells, and 1% (w/v) methylene blue in 
10 mM borate buffer, pH 8.5 was added to stain live cells for 30 mins at room 
temperature. Methylene blue stain was then aspirated from the plates, and cells 
were subsequently washed three times with 10 mM borate buffer, pH 8.5 to 
remove excess stain. 0.1 M HCl : 100% ethanol (1:1 w/v) was then added to 
wells. Plates were shaken to release dye, and absorbance values were read 
using a plate reader at 650 nm. Data was analyzed using Graph Pad Prism 7 by 
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subtracting background absorbance values and fitting sigmoidal curve based on 
the log value of the varying concentrations of cerulenin used in the assay.  
 
2.10. Statistical Analysis 
 Student’s t-test or one-way analysis of variance (ANOVA) with Tukey post 
hoc test where applicable was used for statistical analysis, and p<0.05 was 
considered significant. Results have been presented as mean ± standard 
deviation. Statistical calculations were performed using Microsoft Excel and 
Graph Pad Prism 7. For all statistical calculations for results described herein, at 
least three independent experiments were performed.  
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Chapter 3: Results 
 
3.1. Correlation between FASN and total p65 expression in breast cancer 
cell lines 
 Initially, to begin uncovering the relationship between NF-kB/p65, Western 
blot analysis was performed in three breast cancer cell lines utilized henceforth in 
this study to determine levels of FASN and p65 protein. As shown in Figure 5, 
the highest level of FASN protein was found in the doxorubicin-resistant M3K 
cells, while the lowest level of FASN protein was found in the parental MDA-MB-
468 breast cancer cells. Contrarily, for total p65 level, the cell line containing the 
highest relative protein level was the parental MDA-MB-231 cells, while the M3K 
cells had the lowest p65 level among the three cell lines tested. This observation 
indicates a general negative correlation between FASN and total p65 level in 
breast cancer cells. 
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Figure 5. Correlation between FASN and total p65 expression in breast 
cancer cell lines. 
Western blot analysis showing FASN and total p65 protein level in M3K, 
MDA-MB-468, and MDA-MB-231 cells relative to b-Actin loading control. 
Images from one experiment were quantified using ImageJ. 
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3.2. FASN expression negatively regulates total p65 protein level in breast 
cancer cells 
 It has previously been shown that FASN exhibits inhibitory action towards 
NF-kB (Wu et al. 2016). To determine if FASN regulates NF-kB/p65 at the 
protein level in breast cancer cells, Western blot analysis was performed using a 
previously established drug resistant cell line with stable FASN knockdown 
(M3K/shFASN) derived from MCF7 parental breast cancer cells (Liu et al. 2013). 
I observed that FASN knockdown resulted in an increase in total p65 protein 
level relative to scrambled shRNA control cells (M3K/shScr) (Figure 6B).  
 To validate the above finding, and to ensure that FASN regulation of p65 
expression is not specific to MCF7-derived cells, a stable MDA-MB-436 cell line 
with FASN overexpression (MDA-MB-436/FASN) was established using 
transfection of pcDNA(3.1)-FASN and G418 drug selection (Figure 6A). The 
MDA-MB-436 cell line was chosen due to its clinical relevance as representative 
of the aggressive nature and poor prognosis of the TNBCs. It was also chosen 
due to its low expression of FASN relative to other breast cancer cell lines as a 
way to avoid any potential artefacts associated with overexpression of FASN in 
these cells.  
 Utilizing this newly established overexpression cell line, I observed that 
total p65 protein level was decreased when FASN was overexpressed relative to 
vector-transfected control cells (MDA-MB-436/Vec) (Figure 6B). This indicates 
that there is an inverse relationship in breast cancer cells between FASN and 
total p65 protein level, wherein FASN negatively regulates total p65 protein level. 
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Figure 6. FASN expression negatively regulates total p65 protein level in breast 
cancer cells. 
(A) Western blot verifying and confirming stable FASN overexpression in MDA-
MB-436 breast cancer cells (MDA-MB-436/FASN) compared to vector-
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transfected control cells (MDA-MB-436/Vec). (B) Western blot analysis using 
M3K cells with stable FASN shRNA knockdown compared to scrambled shRNA 
control cells and MDA-MB-436 cells with stable FASN overexpression compared 
to vector-transfected control cells looking at total p65 protein level. Blots were 
quantified using ImageJ. Differences in protein level were determined using 
Student’s t-test. **p<0.01; ***p<0.001. Bar graphs represent three independent 
experiments with standard deviations from the mean.  
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3.3. Pharmacological inhibition of FASN using cerulenin increases total p65 
expression in breast cancer cells 
 Having demonstrated a relationship wherein FASN expression negatively 
regulates p65 protein level, I sought to determine if FASN activity plays a role in 
this process. To explore the role of FASN activity in this mechanism, I utilized a 
common FASN inhibitor known as cerulenin, which binds irreversibly to the b-
ketoacyl synthase domain of FASN, thereby preventing the elongation of the 
growing fatty acid chain via condensation reaction (Vance et al. 1972; Omura 
1976; Moche 1999). Initially, in an effort to determine specific concentrations to 
employ for experimentation in various cell lines, IC50 values were determined for 
cerulenin treatment in the three breast cancer cell lines utilized in this study using 
the Methylene blue cell viability assay (Figure 7A). Similar IC50 values were 
observed for M3K and MDA-MB-231 cells at 8.62 ± 0.39 µM (1.92 ± 0.09 µg/mL) 
and 8.98 ± 0.90 µM (2.00 ± 0.20 µg/mL) respectively, whereas MDA-MB-468 
cells exhibited a significantly lower IC50 value of 6.35 ± 0.16 µM (1.42 ± 0.04 
µg/mL). Representative curves for cell viability in the presence of varying 
concentrations of cerulenin for each cell line are shown in Figure 7B. 
 As a result of the IC50 data obtained for cerulenin with respect to cell 
viability in the three cell lines, M3K, MDA-MB-468, and MDA-MB-231 cells were 
treated for 72 hours with increasing concentrations of cerulenin or vehicle 
(ethanol), and Western blot analysis was performed for total p65 protein level in 
these cell lines. In these experiments, a lower starting concentration for cerulenin 
(1.75 µg/mL) was utilized in MDA-MB-468 cells due to the significantly lower IC50 
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value that was determined for these cells compared to M3K and MDA-MB-231 
cells. With increasing concentrations of cerulenin, there was a resulting dose-
dependent increase in total p65 protein level compared to untreated cells in all 
cell lines tested (Figure 7C). It was also found that cerulenin appeared to induce 
a decrease in FASN expression in all cell lines tested indicating that cerulenin 
indeed binds to and inhibits FASN and may induce its degradation. Overall, these 
findings suggest that FASN activity, similar to FASN expression, also exhibits a 
relationship with NF-kB/p65, wherein FASN negatively regulates total p65 at the 
protein level.  
 
  
47 
 
 
  
0
2
4
6
8
10
12
M3K MDA-MB-468 MDA-MB-231
C
er
ul
en
in
IC
50
(μ
M
)
Cell Line
** **
NS
A
0.5 1.0 1.5 2.0
0
50
100
150
log[Cerulenin], uM
C
el
l V
ia
bi
lit
y
(%
 C
on
tro
l)
M3K
0.5 1.0 1.5 2.0
0
50
100
150
log[Cerulenin], uM
C
el
l V
ia
bi
lit
y
(%
 C
on
tro
l)
MDA-MB-468
0.5 1.0 1.5 2.0
0
50
100
150
log[Cerulenin], uM
C
el
l V
ia
bi
lit
y
(%
 C
on
tro
l)
MDA-MB-231
B
48 
 
 
 
  
Figure 7. Pharmacological inhibition of FASN using cerulenin increases total p65 
expression in breast cancer cells. 
(A) Bar graph representation of methylene blue cell viability assay data indicating 
relative IC50 values for M3K, MDA-MB-468, and MDA-MB-231 cells treated with 
varying concentrations of FASN inhibitor cerulenin or vehicle (ethanol) for 72 
hours. (B) Representative cell viability curves for methylene blue assays in M3K, 
MDA-MB-468, and MDA-MB-231 cells. (C) Western blot analysis using M3K, 
MDA-MB-468, and MDA-MB-231 cells treated with increasing concentrations of 
cerulenin or vehicle (ethanol) for 72 hours probing for total p65 and FASN level. 
Methylene blue assay data was curve-fitted to determine IC50 values using Graph 
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Pad Prism. X-ray film images were quantified using ImageJ. Differences in IC50 
values between cell lines and protein level in Western blots were determined 
using one-way ANOVA with Tukey post hoc test. *p<0.05; **p<0.01. Bar graphs 
represent three independent experiments, wherein error bars denote standard 
deviation from the mean.   
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3.4. Supplementation of breast cancer cells with exogenous palmitate 
ablates FASN-mediated effects on total p65  
 As discussed earlier, the end product of FASN enzymatic activity is the 
16-carbon saturated fatty acid palmitate. As a result, to further investigate the 
role of FASN activity in regulating NF-kB/p65, the potential effects of palmitate on 
NF-kB/p65 were investigated. To this end, M3K/shFASN cells were treated with 
or without 30 µM exogenous palmitate for a period of 48 hours, followed by 
Western blot analysis of p65 expression. I observed exogenous palmitate was 
able to ablate the increases in total p65 protein level that are seen following 
FASN shRNA knockdown (Figure 8A). This finding suggests that palmitate, as 
the product of FASN activity, may play a specific role in mediating the 
downstream effects that are able to result in decreased NF-kB/p65 expression in 
breast cancer cells. 
 The M3K/shScr control cells without FASN knockdown were also treated 
with or without exogenous palmitate to investigate the basal effects on total p65 
in the absence of FASN knockdown (Figure 8B). Palmitate treatment in these 
cells also reduced total p65 level, which indicates that palmitate is able to 
suppress p65 expression induced by FASN knockdown and suppress the basal 
level of p65, suggesting that the ability of palmitate to regulate total p65 level is 
not dependent on a lower level of endogenous free fatty acids in the cell as the 
M3K/shScr cells would exhibit higher levels of circulating free fatty acids. 
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Figure 8. Supplementation of breast cancer cells with exogenous palmitate 
ablates FASN-mediated effects on total p65. 
Western blot analysis wherein M3K/shFASN cells (A) or M3K/shScr control cells 
(B) were treated with vehicle (DMSO) or 30 µM exogenous palmitate for 48 
hours. Cells were then assayed for total p65 expression by probing blots with a 
total p65 antibody. Images were quantified using ImageJ. Significant differences 
were determined using one-way ANOVA with Tukey post hoc test. **p<0.01; 
***p<0.001. Bar graphs with error bars represent three independent experiments 
with standard deviation from the mean.  
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3.5. FASN expression does not affect total p65 at the transcriptional level 
 In order to investigate the potential role of p65 transcriptional effects in the 
ability of FASN expression changes to negatively regulate NF-kB/p65 at the 
protein level, the effects of FASN expression changes on total p65 mRNA were 
examined. Real-time RT-PCR analysis was performed using the M3K/shFASN 
cells along with their control cells, as well as the MDA-MB-436/FASN cells along 
with their control cells following 48 hours cell growth in 6-well plates. Both FASN 
knockdown and FASN overexpression had no significant effect on total p65 
mRNA level relative to their respective control cells (Figure 9). This finding 
suggests that, while FASN has the ability to negatively regulate NF-kB/p65 
protein expression, this regulation does not occur at the transcriptional level.  
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Figure 9. FASN expression does not affect total p65 at the transcriptional level. 
Real-time RT-PCR analysis using M3K cells with stable FASN shRNA 
knockdown compared to scrambled shRNA control cells and MDA-MB-436 cells 
with stable FASN overexpression compared to vector-transfected control cells 
measuring total p65 mRNA level normalized to GAPDH mRNA level 
(housekeeping gene). Potential differences in mRNA levels were determined 
using Student’s t-test. Bar graphs represent three independent experiments with 
standard deviation from the mean. 
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3.6. FASN pharmacological inhibition does not affect total p65 at the 
transcriptional level 
 Having shown that FASN expression changes do not result in an effect on 
p65 mRNA level, I wanted to subsequently investigate the potential effects of 
FASN pharmacological inhibition on total p65 mRNA levels in order to determine 
whether FASN inhibition likely affects total p65 through a mechanism similar to 
that of FASN expression changes. To this end, M3K, MDA-MB-468, and MDA-
MB-231 parental breast cancer cells were treated for 72 hours with cerulenin at 5 
µg/mL, 2.5 µg/mL, or 5 µg/mL respectively or vehicle (ethanol) for a period of 72 
hours. Total RNAs were then isolated from these cells and real-time RT-PCR 
analysis was performed to determine the effects of cerulenin treatment on total 
p65 mRNA. I observed in all three cell lines tested that cerulenin treatment 
resulted in no significant effect on total p65 mRNA levels (Figure 10). This 
finding indicates that the effects of FASN pharmacological inhibition on total p65 
protein level are not a result of effects on the transcription of p65. Also, taken 
together with the lack of a significant effect of FASN expression changes on p65 
mRNA level, this finding suggests that FASN regulation of NF-kB occurs at the 
protein level, potentially impacting either the rate of p65 translation or the rate of 
protein turnover of p65. 
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Figure 10. FASN pharmacological inhibition does not affect total p65 at the 
transcriptional level. 
M3K cells, MDA-MB-468 cells, or MDA-MB-231 cells were treated with 5 µg/mL, 
2.5 µg/mL, or 5 µg/mL cerulenin respectively or vehicle (ethanol) for 72 hours 
followed by real-time RT-PCR analysis measuring total p65 mRNA normalized to 
GAPDH as an internal control. Potential differences in mRNA levels between 
treatment groups were determined using Student’s t-test. Bar graphs represent 
three independent experiments with error bars describing standard deviation 
from the mean. 
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3.7. FASN expression negatively regulates NF-kB activity in breast cancer 
cells 
 Having shown that FASN expression and activity negatively regulates the 
expression of NF-kB/p65, I next sought to determine whether the effects of FASN 
on NF-kB also correlated with an effect on NF-kB activity in addition to the 
effects on p65 at the level of expression. To investigate the relationship between 
FASN and NF-kB activity, I utilized a commercially available luciferase reporter 
assay system that uses a plasmid containing consensus NF-kB binding 
elements, wherein the ability of NF-kB to bind to target gene promoters to carry 
out its transcriptional activity is measured by the induction of luciferase gene 
expression.  
 At 48 hours after transfection of the NF-kB reporter plasmid into 
M3K/shFASN and M3K/shScr control cells, luciferase expression was measured 
as an indicator of NF-kB activity. As shown in Figure 11, when FASN was 
knocked down, an increase in NF-kB activity was observed relative to scrambled 
shRNA control cells. Contrarily, NF-kB activity decreased in MDA-MB-436 cells 
with FASN overexpression compared to the MDA-MB-436/Vec control cells. 
These results are consistent with the observed downregulation of p65 by FASN. 
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Figure 11. FASN expression negatively regulates NF-kB activity in breast cancer 
cells. 
M3K/shFASN cells along with M3K/shScr control cells or MDA-MB-436/FASN 
cells along with MDA-MB-436/Vec control cells were transfected for 48 hours 
with an NF-kB cis-reporter plasmid containing the firefly luciferase gene, along 
with a pRL-TK renilla luciferase plasmid as an internal control for transfection 
efficiency. After 48 hours transfection, dual luciferase assay was performed to 
measure luciferase gene expression as an output of NF-kB activity. Potential 
differences in NF-kB activity between cell line pairs was determined using 
Student’s t-test. **p<0.01. Bar graphs represent three independent experiments, 
wherein error bars represent standard deviation from the mean. 
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3.8. FASN expression negatively regulates TNF-a expression in breast 
cancer cells  
 To confirm the effects of FASN on NF-kB activity, I investigated the effects 
of FASN expression changes on NF-kB target gene expression. Previous 
research in the Zhang lab showed a potential relationship between FASN and the 
canonical NF-kB target gene TNF-a (Liu et al. 2013). As a result, the potential 
effects of FASN expression changes on TNF-a gene expression were 
investigated using real-time RT-PCR analysis with M3K/shFASN cells and 
M3K/shScr control cells, as well as MDA-MB-436/FASN cells and MDA-MB-
436/Vec control cells. RT-PCR analysis showed that FASN shRNA knockdown in 
M3K cells resulted in an increase in TNF-a mRNA level relative to scrambled 
shRNA control cells, whereas overexpression of FASN in MDA-MB-436 cells 
resulted in a decrease in TNF-a mRNA levels relative to vector control cells 
(Figure 12). These results indicate that, similar to the effects of FASN on p65, 
FASN expression negatively regulates TNF-a expression as a downstream target 
gene of NF-kB. 
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Figure 12. FASN expression negatively regulates TNF-a expression in breast 
cancer cells. 
Real-time RT-PCR analysis in M3K/shFASN cells compared to M3K/shScr 
control cells and MDA-MB-436/FASN cells compared to MDA-MB-436/Vec 
control cells looking at TNF-a mRNA levels normalized to GAPDH mRNA levels 
(housekeeping gene) shown as relative expression level to control. Potential 
significant differences were determined using Student’s t-test. *p<0.0.5; 
***p<0.001. Bar graphs represent three independent experiments. Error bars 
represent standard deviation from the mean. 
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3.9. FASN expression positively regulates PARP1 expression in breast 
cancer cells 
 To further confirm the effects of FASN on NF-kB activity, I investigated the 
relationship between FASN and PARP1, a second gene correlated with NF-kB. 
As discussed earlier, PARP1 was implicated in the FASN signaling mechanism, 
wherein FASN induces increases in NHEJ DNA repair activity in cancer cells to 
promote cell survival in the presence of chemotherapeutic and other DNA-
damaging agents. In this mechanism, p65 was shown to negatively regulate 
PARP1 transcription in breast and pancreatic cancer cells, and, specifically, this 
occurred via a composite transcription factor binding site shared with another 
common transcription factor, SP1 (Wu et al. 2016).  
 To verify that PARP1 is positively regulated in breast cancer cells 
downstream of FASN, the effects of FASN expression changes on PARP1 
protein level were measured by Western blot. As shown in Figure 13, when 
FASN was knocked down in M3K cells, there was a resulting decrease in PARP1 
protein level relative to scrambled shRNA control cells. On the other hand, when 
FASN was overexpressed in MDA-MB-436 cells, this led to a corresponding 
increase in PARP1 protein level compared to vector control cells.  
 This suggests that FASN indeed does positively regulate PARP1 
expression in correlation with the negative regulation of NF-kB/p65 in breast 
cancer cells. Taken in context with the effects of FASN on NF-kB reporter 
activity, as well as the effects of FASN on the NF-kB target gene TNF-a, this 
result also indicates that FASN negatively regulates NF-kB activity. 
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Figure 13. FASN expression positively regulates PARP1 expression in breast 
cancer cells. 
Western blot analysis using M3K/shFASN cells and M3K/shScr control cells, as 
well as MDA-MB-436/FASN cells and MDA-MB-436/Vec control cells probing for 
PARP1 protein. X-ray film images were quantified using ImageJ. Potential 
significant differences between groups were determined using Student’s t-test. 
*p<0.05; ***p<0.001. Bar graphs are a representation of three independent 
experiments, wherein error bars indicate standard deviation from the mean. 
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3.10. FASN negatively regulates p65 protein stability 
 Thus far, the results in this thesis have demonstrated that FASN 
expression and activity negatively regulates p65 at the protein level but does not 
affect NF-kB/p65 transcription. As a result, I next sought to determine the 
mechanism responsible for the negative effects exerted by FASN on p65 protein. 
To this end, I hypothesized that FASN may impact p65 protein stability.  
 To investigate the potential role of FASN in regulating p65 protein stability, 
M3K/shFASN cells or M3K/shScr control cells were utilized in a pulse-chase 
assay, wherein cells were harvested at 8 hour intervals for a total chase period of 
32 hours following washout of radiolabeled 35S-Methionine. Immunoprecipitation 
for total p65 and SDS-PAGE was performed using the harvested protein to 
determine any potential differences in the rate of protein turnover between the 
two cell lines, and the precipitated p65 was subsequently quantified using 
scintillation counting. 
 As shown in Figure 14, total p65 protein decreased at a noticeably faster 
rate in M3K/shScr cells compared to M3K/shFASN cells. Specifically, when p65 
protein half-life was determined using Graph Pad Prism, I observed that FASN 
knockdown resulted in a substantially higher half-life (19 hours) compared to that 
in the scrambled shRNA control cells (6 hours). This finding was similar to 
previously published findings for p65 half-life for WT p65 and a mutated p65 
exhibiting decreased protein stability (Ryo et al. 2003). This result suggests that 
increased FASN expression in breast cancer cells results in decreased p65 
protein stability. 
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Figure 14. FASN negatively regulates p65 protein stability. 
35S-Methionine pulse-chase analysis using M3K/shFASN cells and M3K/shScr 
control cells. Cells were incubated in the presence of 35S-Methionine for 2 hours 
prior to washout and incubation in normal media for 32 hours. Cells were 
harvested every 8 hours for total p65 immunoprecipitation, SDS-PAGE, and 
Western blot analysis. X-ray film was developed and total p65 bands were 
quantified using scintillation counting. Protein half-life was determined using 
Graph Pad Prism, and data was graphed using one-phase exponential decay for 
curve-fitting. Graph is representative of three independent experiments. Error 
bars represent standard deviation from the mean. 
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3.11. FASN induces p65 proteasomal degradation 
 Having shown that FASN can lead to reduced p65 protein stability and, as 
a result, an increase in degradation of p65, I next wanted to determine the 
mechanism behind FASN-mediated degradation of p65. NF-kB/p65 has been 
shown to be degraded through the proteasomal pathway (Saccani et al. 2004). 
As a result, I hypothesized that FASN may promote degradation of p65 via the 
proteasome. As shown in Figure 15A, when MDA-MB-436/FASN cells were 
treated with 2 µM MG132 for 24 hours to block proteasomal degradation of 
proteins, the ability of FASN to reduce p65 protein level was ablated, and a 
rescue in p65 protein level was observed.  
 In order to investigate the effects of proteasome inhibition on total p65 
level in breast cancer cells at the basal level, MDA-MB-436/Vec control cells 
were treated with 2 µM MG132 or vehicle for 24 hours before Western blot 
analysis was performed. As shown in Figure 15B, though there appeared to be a 
slight trend towards an increase in total p65 level with MG132 treatment in MDA-
MB-436/Vec cells, this trend was not significant compared to vehicle-treated 
cells. This finding suggests that the rescue effect on total p65 level that was seen 
with proteasome inhibition in Figure 15A is in response to the loss in total p65 
level driven by increases in FASN expression rather than a global basal effect on 
p65 level resulting from consistent degradation of the protein. 
 Next, a previously generated MCF7 cell line with stable FASN 
overexpression (MCF7/FASN) (Liu et al. 2008) was utilized to confirm that 
blocking proteasomal degradation with MG132 prevents the ability of FASN to 
65 
reduce p65 protein level. As shown in Figure 15C, when MCF7/FASN cells were 
treated with 2 µM MG132 for 24 hours, a rescue in p65 protein level was 
observed relative to vehicle-treated cells. Taken together, these results suggest 
that a high level of FASN expression promotes the degradation of p65 through 
the proteasome, and that blocking proteasomal degradation can rescue FASN 
downregulation of protein. 
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Figure 15. FASN induces p65 proteasomal degradation. 
Western blot analysis of (A) MDA-MB-436/FASN cells, (B) MDA-MB-436/Vec 
control cells, and (C) MCF7/FASN cells treated with 2 µM MG132 for 24 hours 
compared to cells treated with vehicle (DMSO) for total p65. X-ray film images 
were quantified using ImageJ. Potential significant differences were determined 
using one-way ANOVA with Tukey post hoc test or Student’s t-test. *p<0.05; 
**p<0.01. Bar graphs represent three independent experiments. Error bars 
delineate standard deviation from the mean. 
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3.12. FASN induces ubiquitination of p65 
 Having seen that increases in FASN expression result in increased 
proteasomal degradation of p65, I wanted to determine whether FASN 
expression could also impact ubiquitination of p65 as a signal for the cell to 
trigger proteasomal degradation, as proteasomal degradation of p65 has been 
heavily linked to p65 ubiquitination by a variety of different E3 ubiquitin ligases 
(Collins et al. 2016).  
 In order to investigate ubiquitination levels of p65 with changes in FASN 
expression, M3K/shFASN cells along with M3K/shScr control cells, as well as 
MDA-MB-436/FASN cells along with MDA-MB-436/Vec control cells were initially 
transfected with pcDNA(3.1)-p65-FLAG for 24 hours, followed by 4 hour 
treatment with 2 µM of the proteasome inhibitor MG132. MG132 treatment was 
used to prevent any proteasomal degradation of p65-FLAG proteins that would 
occur following ubiquitination of those proteins. As a result, this will allow for an 
accurate representation of the total level of ubiquitinated-p65-FLAG that is seen 
downstream of FASN expression changes.  
 After harvesting cells, p65-FLAG proteins were then immunoprecipitated, 
and Western blot analysis was performed using a ubiquitin antibody to measure 
the level of ubiquitination of p65-FLAG proteins. Western blot analysis was also 
performed using total cell lysate to measure levels of p65-FLAG prior to 
immunoprecipitation in the presence of MG132 to prevent degradation of FLAG-
p65 proteins, as well as to measure levels of b-actin in total cell lysate as a 
control to attempt to ensure equal amounts of protein utilized in the 
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immunoprecipitation of p65-FLAG. Also, to control for possible transfection 
efficiency differences in ectopic expression of p65-FLAG between cell lines, 
quantification was performed using ImageJ, wherein the ratio of ubiquitinated-
p65-FLAG levels to input level of p65-FLAG was determined.  
 As shown in Figure 16, M3K/shFASN cells exhibited decreased 
ubiquitination of p65-FLAG compared to M3K/shScr control cells. On the 
contrary, when FASN was overexpressed in MDA-MB-436 cells, p65-FLAG 
ubiquitination levels were increased compared to MDA-MB-436/Vec control cells. 
This finding, in correlation with the effects of FASN on proteasomal degradation, 
suggests that increased FASN expression results in increased p65 ubiquitination. 
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Figure 16. FASN induces ubiquitination of p65. 
Western blot analysis of p65-FLAG protein immunoprecipitated from 
M3K/shFASN cells or M3K/shScr control cells, as well as MDA-MB-436/FASN 
cells or MDA-MB-436/Vec control cells transfected with p65-FLAG for 24 hours 
followed by treatment with 2 µM MG132 for 4 hours. Western blots were probed 
with an a-ubiquitin antibody. Total protein lysate was subjected to Western blot 
for input levels as a loading control, wherein Western blots were probed for p65-
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FLAG and b-actin. Images are representative of three independent experiments 
and were quantified using ImageJ. Potential significant differences in 
ubiquitinated-p65-FLAG were determined using Student’s t-test. *p<0.05; 
***p<0.001. Error bars represent standard deviation from the mean. 
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3.13. Kinase inhibition reduces p65 protein level 
 The data presented in this thesis to this point shows that FASN negatively 
regulates p65 by decreasing its stability, likely through proteasomal degradation. 
Therefore, I next sought to determine the mechanism responsible for the 
disruption in p65 protein stability mediated by FASN. Previous evidence suggests 
that phosphorylation of certain sites on the p65 subunit of NF-kB, including 
Thr254, Ser276, and Ser536 are involved in promoting the activation of the NF-
kB signaling pathway and may be involved in regulating p65 protein stability 
(Christian et al. 2016).  
 As a result, I sought to investigate the potential role of kinase activity in 
mediating the effects of FASN on p65 protein. To this end, M3K/shFASN cells 
were treated with or without the pan-kinase inhibitor staurosporine, which binds 
to the ATP binding pocket of kinases, at a concentration of 100 nM for 2 hours 
followed by stimulation with 50 µg/mL TNF-a for 1 hour, wherein cells were 
harvested and Western blot analysis was performed to measure the effects of 
kinase inhibition with staurosporine on total p65 level and on levels of 
phosphorylation of p65 at Ser536. TNF-a stimulation was used specifically in an 
effort to induce detectable levels of phosphorylation of p65 at Ser536, which was 
measured to control for effective kinase inhibition and to investigate a potential 
link between FASN and p65 phosphorylation. TNF-a was chosen to stimulate 
NF-kB in this context, as opposed to other mediators of NF-kB activation, due to 
its established relationship with FASN. In a previous study, it was observed that, 
in both the presence and absence of doxorubicin treatment to induce DNA 
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damage, knockdown of FASN expression in breast cancer cells resulted in an 
upregulation of TNF-a expression and promoter activity, as well as NF-kB activity 
(Liu et al. 2013). In this study, FASN overexpression also negatively regulated 
TNF-a expression. As a result, it appears likely that TNF-a is an upstream 
regulator of NF-kB in the mechanism of NF-kB activation downstream of 
decreased FASN expression. Western blot analysis was then performed to 
investigate the effects of staurosporine treatment on total p65 protein.  
 As shown in Figure 17, kinase inhibition ablated the ability of FASN 
knockdown in M3K breast cancer cells to cause increases in total p65 protein 
level and subsequently resulted in a reduction in total p65 level to a level similar 
to that of M3K/shScr control cells. It was also determined that FASN knockdown 
resulted in an increase in phosphorylation of p65 at Ser536, while kinase 
inhibition with staurosporine ablated these increases. As a result, there may be a 
link between FASN, kinase activity, and p65 protein expression.  
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Figure 17. Kinase inhibition reduces p65 protein level. 
Western blot analysis of M3K/shFASN cells treated with 100 nM staurosporine or 
vehicle (DMSO) for 2 hours followed by stimulation with 50 µg/mL TNF-a for 1 
hour prior to harvesting cells for Western blot to activate the NF-kB signaling 
pathway. X-ray film images were quantified using ImageJ. Potential differences in 
p65 level were determined using one-way ANOVA with Tukey post hoc test. 
**p<0.01. Bar graphs are a representation of three independent experiments. 
Error bars represent standard deviation from the mean. 
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3.14. FASN expression negatively regulates p65 Ser536 phosphorylation 
 Due to the apparent link between FASN, kinase activity, and p65 protein 
stability, I next attempted to link FASN with specific p65 phosphorylation sites. As 
stated earlier in this thesis, phosphorylation of the p65 subunit of NF-kB has long 
been characterized as being correlated in many cases with NF-kB activation, and 
the phosphorylation site most commonly associated with NF-kB activation is 
Ser536 (Chen et al. 2005). Further, it has been found that phosphorylation of 
Ser536 of p65 takes place following Ser32 and Ser36 phosphorylation of IkBa 
and alters the timing of translocation of p65 to the nucleus, thereby suggesting 
this phosphorylation event may affect p65 interaction with IkBa and potentially its 
trafficking and stability (Mattioli et al. 2004). 
 As a result of this established relationship and the apparent link between 
FASN and this phosphorylation site determined with staurosporine treatment, the 
potential effects of FASN expression changes on p65 phosphorylation at Ser536 
were investigated. As shown in Figure 18, when FASN was knocked down in 
M3K cells, this led to an increase in p65 Ser536 phosphorylation relative to 
scrambled shRNA control cells when the NF-kB pathway was stimulated using 
TNF-a treatment, whereas, when FASN was overexpressed in MDA-MB-436 
cells, this led to a corresponding decrease in p65 Ser536 phosphorylation 
relative to vector control cells in the presence of TNF-a stimulation. From this 
data, FASN appears to negatively regulate the phosphorylation of p65 at Ser536.  
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Figure 18. FASN expression negatively regulates p65 Ser536 phosphorylation. 
Western blot analysis using M3K/shFASN cells along with M3K/shScr control 
cells and MDA-MB-436/FASN cells along with MDA-MB-436/Vec control cells for 
phosphorylation of p65 at Ser536. Cells were stimulated with 50 µg/mL TNF-a for 
1 hour prior to harvesting cells for Western blot to activate the NF-kB signaling 
pathway. X-ray film images were quantified using ImageJ. Potential differences 
between groups were analyzed using Student’s t-test. **p<0.01. Bar graphs 
represent three independent experiments. Error bars denote standard deviation 
from the mean. 
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3.15. FASN activity negatively regulates p65 Ser536 phosphorylation 
 I next sought to investigate the relationship between FASN activity and 
p65 Ser536 phosphorylation. To do so, breast cancer cell lines M3K, MDA-MB-
468, and MDA-MB-231 were pre-treated with increasing concentrations of the 
FASN inhibitor cerulenin for a period of 72 hours, then stimulated with 50 µg/mL 
TNF-a for 1 hour before cell lysate preparation and Western blot analysis of 
Ser536-phosphorylated p65 and total p65. As shown in Figure 19, increasing 
concentrations of cerulenin resulted in a dose-dependent increase in 
phosphorylation of p65 at Ser536, as well as a dose-dependent increase in total 
p65 as seen earlier in all three breast cancer cell lines tested. From this data, I 
can conclude that, similar to FASN expression, FASN activity negatively 
regulates p65 phosphorylation at Ser536, thereby suggesting that Ser536 could 
potentially be involved in the regulation of total p65 level.  
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Figure 19. FASN activity negatively regulates p65 Ser536 phosphorylation. 
Western blot analysis of M3K, MDA-MB-468, and MDA-MB-231 cells pre-treated 
for 72 hours with increasing concentrations of cerulenin, followed by stimulation 
with 50 µg/mL TNF-a for 1 hour. Blots were probed for P-p65 Ser536 and total 
p65. X-ray film images were quantified using ImageJ. Potential significant 
differences between groups were determined using one-way ANOVA with Tukey 
post hoc test. *p<0.05; **p<0.01. Bar graphs for quantification are representative 
of three independent experiments. Error bars represent standard deviation from 
the mean. 
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3.16. p65 Ser536 phosphorylation does not appear to be involved in 
regulating p65 protein stability 
 Based on the above observations, I hypothesized that phosphorylation of 
Ser536 may play a role in regulating p65 protein stability. In order to test this 
hypothesis, I utilized a kinase inhibitor, BMS-345541, specific to IKK, as IKKa 
and IKKb are the primary kinases known to be responsible for phosphorylation of 
p65 at Ser536 as described earlier (Buss et al. 2004; Lawrence et al. 2005; 
Sakurai et al. 1999; Sizemore et al. 2002). This inhibitor has been found to inhibit 
IKKb-mediated phosphorylation of IkBa with high potency, exhibiting an IC50 of 
0.3 µM against IKKb (Burke et al. 2003). Although BMS-345541 exhibits 
somewhat lower potency towards IKKa, BMS-345541 has also been found to 
inhibit this isoform significantly with an IC50 of 4 µM. It is also believed this 
inhibitor has substantial selectivity towards IKKb and IKKa in that the drug did not 
inhibit other kinases at concentrations up to 100 µM (Burke et al. 2003). 
 Based on the experimentally-determined IC50 values of BMS-345541 in 
inhibiting both IKK isoforms, M3K/shFASN cells were treated with 5 µM BMS-
345541 or vehicle for a period of 2 hours, followed by 1 hour treatment with 50 
µg/mL TNF-a to stimulate activation of the NF-kB pathway, wherein cell lysates 
were prepared, and Western blot analysis was performed for Ser536-
phosphorylated p65 and total p65. As shown in Figure 20, FASN knockdown in 
M3K cells led to increases in both phosphorylation of p65 at Ser536 and total p65 
level. However, when IKK was inhibited with BMS-345541, increases in 
phosphorylation of p65 that were seen with FASN knockdown were ablated, as 
80 
was IkBa phosphorylation, but there was no effect on the increases in total p65 
that were seen following FASN knockdown. This result indicates that, despite the 
ability of FASN expression changes to affect Ser536 phosphorylation of p65, the 
effects of FASN expression on p65 Ser536 phosphorylation are not responsible 
for the effects of FASN on total p65 protein level.  
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Figure 20. p65 Ser536 phosphorylation does not appear to be involved in 
regulating p65 protein stability. 
Western blot analysis of M3K/shFASN cells treated with or without 5 µM IKK 
inhibitor BMS-345541 or vehicle (DMSO) for 2 hours followed by 50 µg/mL TNF-
a for an additional hour. Western blots were probed for phospho-IkBa, P-p65 
(Ser536), and total p65. Images were quantified using ImageJ. Differences 
between treatment groups were determined using one-way ANOVA with Tukey 
post hoc test. *p<0.05; **p<0.01. Bar graphs are representative of three 
independent experiments. Error bars represent standard deviation from the 
mean. 
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3.17. FASN regulation of p65 protein stability involves Thr254 of p65 
 Another p65 phosphorylation site that has been linked with NF-kB 
activation is Thr254. Further, phosphorylation of p65 at Thr254 has also been 
directly linked to increased p65 protein stability (Ryo et al. 2003). I observed that, 
when Thr254 was mutated in mouse embryonic fibroblast (MEF) cells, p65 
protein stability was substantially reduced relative to WT p65. Also, when the 
proteasome inhibitor MG132 was introduced, this resulted in a rescue in total p65 
level in the presence of the Thr254 mutation.  
 As a result, I hypothesized that FASN may impact p65 protein stability by 
modulating the phosphorylation of p65 at Thr254 or otherwise by modulating 
proteins that interact with this phosphorylation site. In order to test the potential 
involvement of Thr254 in FASN regulation of p65, I initially performed site-
directed mutagenesis to mutate the Thr254 site to Ala. This was performed using 
a pcDNA(3.1)-WT-p65-FLAG plasmid generously provided by Dr. Tao Lu as a 
template.  
 Following generation of the T254A mutant plasmid, I next transfected both 
M3K/shFASN cells and M3K/shScr control cells with either empty pcDNA(3.1) 
vector as a negative control, pcDNA(3.1)-WT-p65-FLAG, or pcDNA(3.1)-p65-
T254A-FLAG for 24 hours, followed by a time course treatment using 
cycloheximide, which halts global protein synthesis in the cell, at 60 µg/mL for 0 
to 12 hours, harvesting cells every 4 hours. After harvesting cells at the indicated 
time points, Western blot analysis was performed using a FLAG tag antibody in 
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order to determine the effects of cycloheximide treatment on ectopic p65 
expression in the cell over time.  
 As shown in Figure 21A, protein half-life of p65 in M3K/shFASN cells 
transfected with WT p65 is increased compared to M3K/shScr control cells 
transfected with WT p65, indicating, similar to endogenous p65, that high levels 
of FASN expression can reduce p65 protein stability. However, mutation of 
Thr254 to Ala in M3K/shFASN cells leads to a disruption in p65 protein stability 
compared to cells expressing WT p65 (Figure 21B). This finding suggests that 
phosphorylation of p65 at Thr254 is important for maintaining p65 protein stability 
in breast cancer cells.  
 Also, mutation of Thr254 to Ala in M3K/shScr control cells results in a 
highly disrupted half-life of p65-FLAG, further supporting the conclusion that the 
Thr254 site is involved in the ability of FASN to negatively regulate p65 protein 
stability (Figure 21B). In Figure 21C, the relative protein level of total p65 
present in each condition over the 12 hour time period is shown graphically using 
one-phase exponential decay. As shown in the graph, only M3K/shFASN cells 
transfected with WT-p65-FLAG exhibit stable total p65 protein levels over this 
time course compared to cells with mutated p65-FLAG at Thr254 and M3K/shScr 
control cells transfected with WT-p65-FLAG. Taken together, these data suggest 
that high levels of FASN expression negatively regulate p65 protein stability, 
wherein, when FASN level is high, this may trigger a signaling mechanism 
responsible for disrupting phosphorylation of p65 at Thr254 and resulting in 
decreased p65 protein stability.  
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Figure 21. FASN regulation of p65 protein stability involves Thr254 of p65. 
(A and B) Western blot analysis of M3K/shFASN cells and M3K/shScr control 
cells transfected with (A) wild type p65-FLAG or (B) p65-FLAG with T254A 
mutation, treated with 60 µg/mL cycloheximide for 0 to 12 hours, and harvested 
at the indicated time points before blotting and probing for FLAG tag recognizing 
tagged p65. (C) Graphical analysis performed in Graph Pad Prism indicating the 
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percent loss in p65-FLAG protein over time in the presence of cycloheximide in 
all cell lines tested. Western blots were quantified using ImageJ. Graph was 
generated using Graph Pad Prism one-phase exponential decay and is 
representative of three independent experiments. Error bars represent standard 
deviation from the mean. 
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3.18. Pin1 knockdown in breast cancer cells decreases total p65 expression 
 It has been reported that the peptidyl-prolyl cis/trans isomerase Pin1 plays 
a significant role in mediating the enhancement in p65 protein stability that is 
seen in the presence of p65 Thr254 phosphorylation (Ryo et al. 2003). 
Specifically, when p65 is present in the nucleus following its activation and is not 
bound by the inhibitory subunit IkBa, the Thr254 site of p65 is exposed, allowing 
for its phosphorylation (Ryo et al. 2003). This then creates a binding site for Pin1, 
which subsequently binds to the Thr254-Pro motif and likely carries out its 
isomerization activity on p65. The loss of Pin1 was shown to disrupt p65 nuclear 
accumulation and significantly reduce p65 stability (Ryo et al. 2003). 
 In order to investigate the potential role for Pin1 in the relationship 
between p65 Thr254 and p65 protein stability in breast cancer cells, siRNA 
targeting Pin1 to knock down Pin1 expression was utilized. Western blot analysis 
utilizing Pin1 siRNA knockdown in M3K/shFASN cells showed that decreasing 
Pin1 expression results in a reduction in total p65 protein level relative to 
M3K/shFASN cells transfected with scrambled control siRNA (Figure 22). This 
finding suggests that Pin1 assists in mediating the increases in p65 protein 
stability that are seen when FASN expression is lost. 
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Figure 22. Pin1 knockdown in breast cancer cells decreases total p65 
expression. 
Western blot analysis of M3K/shFASN cells transfected with siRNA targeting 
Pin1 or scrambled control siRNA for 48 hours blotting for total p65 and Pin1 to 
verify knockdown. Images were quantified using ImageJ. Potential significant 
differences between groups were determined using one-way ANOVA with Tukey 
post hoc test. *p<0.05; **p<0.01. Bar graphs are representative of three 
independent experiments. Error bars represent standard deviation from the 
mean. 
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3.19. Pharmacological inhibition of Pin1 in breast cancer cells reduces total 
p65 expression 
 Ryo et al. showed that cells that did not express Pin1 exhibited decreased 
p65 protein stability (Ryo et al. 2003). This finding suggested that the prolyl 
isomerase activity of Pin1 is responsible, in part, for maintaining the stability of 
p65, and that this coincides with phosphorylation of p65 at Thr254. As a result, I 
sought to investigate the potential role of Pin1 activity in regulating total p65 
protein level. In order to investigate this potential role, I utilized dipentamethylene 
thiuram monosulfide (DTM), which has been characterized as a competitive 
inhibitor that specifically inhibits the pepidyl-prolyl cis/trans isomerase activity of 
Pin1 (Tatara et al. 2009).  
 Specifically, M3K/shFASN cells were treated with 10 µM DTM or vehicle 
(DMSO) for a period of 48 hours before performing Western blot analysis to 
determine the effects of Pin1 inhibition on total p65 level. As shown in Figure 23, 
inhibition of Pin1 with DTM resulted in a significant decrease in total p65 level in 
M3K/shFASN cells relative to control treatment. In fact, treatment with DTM 
completely ablated the increases in total p65 level that are seen with FASN 
knockdown and returned p65 level to a level similar to that of vehicle-treated 
M3K/shScr control cells. This finding, along with the effects of Pin1 siRNA on 
p65, indicates that the isomerase activity of Pin1 plays a significant role in 
mediating p65 protein stability in the absence of FASN.   
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Figure 23. Pin1 pharmacological inhibition in breast cancer cells reduces total 
p65 expression. 
M3K/shFASN cells treated with 10 µM DTM or vehicle (DMSO) for 48 hours 
followed by Western blot analysis for total p65 and compared to M3K/shScr 
control cells treated with vehicle (DMSO). Images were quantified using ImageJ. 
Potential differences between groups were calculated using one-way ANOVA 
with Tukey post hoc test. **p<0.01. Bar graphs are representative of three 
independent experiments. Error bars indicate standard deviation from the mean.  
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3.20. Proposed mechanism of FASN regulation of NF-kB/p65 
 In summary, when FASN expression is high in breast cancer cells, FASN 
activity results in increased production of the saturated fatty acid palmitate as the 
primary product. Palmitate then plays a role in an unknown signaling cascade 
that culminates in either preventing the phosphorylation of p65 at Thr254 or, 
otherwise, disrupting the phosphorylation of p65 at Thr254. As a result of the lack 
of phosphorylated p65, Pin1 is unable to bind p65 at its Thr254-Pro motif. Due to 
the lack of Pin1 binding, p65 is not isomerized and does not undergo a 
conformational change. Consequently, p65 likely is bound by the inhibitory 
subunit IkBa, as was demonstrated in the absence of Pin1 binding by Ryo et al. 
As a result, continuous activation of the NF-kB signaling pathway does not occur, 
and p65 is targeted for poly-ubiquitination and proteasomal degradation. 
Ultimately, in the overall mechanism of FASN regulation of NHEJ DNA repair, 
this process subsequently has the effect of relieving the ability of NF-kB to inhibit 
PARP1, thereby resulting in an increase in PARP1 expression. This mechanism 
is shown graphically in Figure 24A.  
 Contrarily, when FASN expression is low in breast cancer cells, or when 
FASN is inhibited pharmacologically, FASN activity is disrupted, resulting in 
decreased production of its catalytic product palmitate. As a consequence of the 
loss of FASN and palmitate, p65 is likely able to be phosphorylated at Thr254. 
This phosphorylation event signals for the binding of Pin1, and Pin1 
subsequently carries out its peptidyl-prolyl cis/trans isomerase activity on p65, 
resulting in p65 undergoing a conformational change. This conformational 
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change disrupts the ability of p65 to bind with IkBa but does not affect its 
interaction with its heterodimeric partner p50 (Ryo et al. 2003). As a result, the 
p65/p50 heterodimer is able to remain in the nucleus, resulting in sustained NF-
kB activation and the transcription of specific target genes such as TNF-a. This 
mechanism is shown graphically in Figure 24B. 
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Figure 24. Proposed mechanism of FASN regulation of NF-kB/p65. 
(A) When FASN expression is high in breast cancer cells, palmitate is produced 
as the end product of FASN activity. An unknown signaling cascade then leads to 
either the dephosphorylation of p65 at Th254 or leads to the inhibition of kinase 
activity that prevents phosphorylation of p65 at Thr254. As a result, Pin1 does 
not recognize and bind p65, and p65 does not undergo a conformational change. 
Instead, p65 is likely bound by the NF-kB inhibitory subunit IkBa and exported 
from the nucleus to be degraded through the proteasome. Loss of p65 prevents 
sustained NF-kB activation and, subsequently, allows for an upregulation of 
PARP1. (B) When FASN expression is low or inhibited pharmacologically in 
breast cancer cells, palmitate production and free palmitate present in the cell is 
reduced. Reduced palmitate level either disrupts a signaling cascade that results 
in dephosphorylation of p65 at Thr254 or rather allows for increased activity of an 
unknown kinase that acts to phosphorylate p65 at Thr254. Presence of p65 in its 
phosphorylated form then allows for the binding of Pin1, which binds the 
phospho-Thr254-Pro motif of p65 and induces a conformational change in the 
p65 protein structure, which serves to confer increased p65 protein stability and 
disrupts the potential interaction between p65 and IkBa. This increased p65 
protein stability leads to increased p65 nuclear residence and accumulation, as 
well as increased NF-kB activity. 
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Chapter 4: Discussion 
 
4.1. Summary of Findings 
 Previous research has uncovered a mechanism wherein FASN 
contributes to increased cancer cell survival through the upregulation of NHEJ 
DNA repair activity involving the inhibition of NF-kB (Wu et al. 2016). This thesis 
explores the specific pathway responsible for FASN regulation of NF-kB in breast 
cancer cells with the goal of uncovering in detail the cell signaling relationship 
exhibited by these two genes. As summarized schematically in Figure 24, the 
results shown in this thesis suggest that, when FASN expression is high in breast 
cancer cells, as is often the case in clinical cases of breast cancer, the high level 
of FASN expression and corresponding high amounts of palmitate are able to 
negatively regulate expression of total p65 at the protein level, while not affecting 
p65 at the level of transcription. It was also found that pharmacological inhibition 
of FASN with cerulenin produces the same effect on total p65. This negative 
regulation of NF-kB/p65 also was determined to correspond to negative 
regulation of NF-kB activation involving a reduction in NF-kB transcriptional 
activity and a disruption in the ability of NF-kB to regulate gene expression of 
TNF-a and PARP1. In addition, it was determined that high levels of FASN 
expression result in a reduction in p65 protein stability, and that the increased 
protein turnover of p65 with high FASN expression resulted from increased p65 
poly-ubiquitination and proteasomal degradation. Further, I observed that the 
regulation of p65 protein stability involves the phosphorylation site Thr254, in that 
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mutation of this residue disrupts p65 protein stability, even in the absence of high 
levels of FASN expression. A lack of phosphorylation of this site also likely 
affects p65 stability specifically by preventing the interaction of p65 with the 
peptidyl-prolyl cis/trans isomerase Pin1, as knockdown and pharmacological 
inhibition of Pin1 resulted in a decrease in p65 protein level. 
 In the bigger picture of FASN signaling in breast cancer cells that Dr. 
Zhang and his colleagues have been unraveling over the last several years of 
research, this process prevents the ability of NF-kB to inhibit PARP1, which has 
been shown to be specifically involved in up-regulating mechanisms of DNA 
repair through NHEJ activity to confer increased cancer cell survival (Wu et al. 
2016).  
 
4.2. Impact of FASN Inhibition on FASN Expression 
 Cerulenin is a long-studied small molecule inhibitor of the KS domain of 
FASN. In this thesis, I observed that inhibition of FASN with cerulenin not only 
produced cellular effects on NF-kB/p65, but also led to a corresponding decrease 
in FASN expression, as indicated by reduced FASN protein level by Western 
blot. Many studies have shown similar depletions in FASN expression with 
cerulenin treatment (Li et al. 2014; Bauerschlag et al. 2015; Lee et al. 2017; Tian 
et al. 2018). Many potential mechanisms could be responsible for this reduction 
in expression that occurs with FASN inhibition. One potential explanation is that 
the binding of cerulenin to the KS domain of FASN could induce a conformational 
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change in the FASN protein structure that disrupts the protein stability of FASN to 
induce increased FASN degradation.  
 Research has shown that FASN expression can be sustained through 
FASN deubiquitination by the isopeptidase ubiquitin-specific protease-2a 
(USP2a), which prevents FASN proteasomal degradation and was first 
determined in prostate cancer cells (Graner et al. 2004). This finding suggests 
the possibility that FASN inhibition with cerulenin or other FASN inhibitors may 
prevent the ability of ubiquitination marks to be removed from FASN, potentially 
due to reduced access of deubiquitinating enzymes to FASN in the presence of 
inhibitor binding or through another mechanism.  
 Another study also found that acetylation of FASN by histone 
acetyltransferase 8 (KAT8) promoted the association of FASN with an E3 
ubiquitin ligase to result in FASN proteasomal degradation, whereas the removal 
of acetylation marks catalyzed by histone deacetylase 3 (HDAC3) resulted in 
increased FASN expression (Lin et al. 2016). This suggests that FASN inhibition 
has the potential to either promote the acetylation of FASN or to reduce access 
of HDAC3 or other deacetylating enzymes to FASN proteins to result in the 
promotion of FASN degradation. The possibility that cerulenin or other inhibitors 
targeted against FASN induce FASN degradation through these mechanisms 
could be investigated by utilizing proteasome inhibitors in the presence of FASN 
inhibition. 
 Interestingly, a study in ovarian cancer cells has shown that, while 
cerulenin treatment reduced FASN expression at the protein level, 
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supplementation of cells with palmitate in combination with cerulenin treatment 
appeared to result in a rescue in FASN protein level (Bauerschlag et al. 2015). 
This may indicate that free fatty acid levels in the cell may impact the expression 
level of FASN in the presence of FASN inhibition. Further, it is widely believed 
that the accumulation of malonyl-CoA that results from FASN inhibition with 
cerulenin and other inhibitors is a main cause of cancer cell apoptosis 
(Menendez and Lupu 2007). As a result, it is possible that the accumulation of 
malonyl-CoA and other fatty acid biosynthesis intermediates play a role in the 
destabilization of FASN in the presence of FASN inhibition.  
  
4.3. Potential Causes for FASN and Palmitate Effects on p65 
Phosphorylation 
  The data presented in this thesis have shown that FASN affects the 
stability of p65 protein, and that the specific phosphorylation site Thr254 is 
involved in p65 protein stability, thereby indicating that FASN may affect 
phosphorylation of p65 at this site. Though it appears palmitate is likely involved 
in regulating p65 protein stability downstream of FASN according to the data in 
Figure 8 of this thesis, it remains largely unclear how FASN is able to impact 
phosphorylation of p65 at Thr254 to affect p65 protein stability. As discussed 
earlier in the introduction, palmitate is known to play a significant role in cancers 
through a variety of processes. Specifically, it has been shown that protein 
modification through palmitoylation of cysteine residues can have a direct effect 
on the activity of signaling molecules such as Wnt proteins and Ras GTPases 
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(Rohrig and Schulze 2016; Eisenberg et al. 2013). As a result, a logical 
hypothesis for the role of FASN in affecting phosphorylation of p65 at Thr254 
would likely begin with investigation into a potential role for protein palmitoylation, 
whether that be directly on p65 to perhaps affect the conformation of the protein 
and disrupt phosphorylation, or on a different protein to induce a subsequent 
effect on p65 phosphorylation.  
 As shown in Appendix A, blocking palmitoylation with an inhibitor resulted 
in a decrease in total p65 protein level in M3K doxorubicin resistant breast 
cancer cells. This finding suggests that high FASN expression does not lead to 
direct palmitoylation of p65 to suppress p65 expression. Further supporting this 
finding, many proteomics studies have been carried out to determine 
palmitoylated proteins in various mammalian genomes. Compilation studies of 
these protein palmitoylomes, though finding many proteins appearing to be 
palmitoylated that have significant roles in cancer, did not find p65 or any other 
NF-kB family proteins to be palmitoylated (Sanders et al. 2015; Ko and Dixon 
2018).  
 Though it does not appear likely FASN leads to the palmitoylation of p65, 
it is possible FASN impacts p65 expression through an indirect mechanism that 
involves palmitoylation, seeing as blocking palmitoylation activity resulted in a 
decrease in p65 protein level. In such a mechanism, when FASN expression is 
high, FASN production of palmitate could lead to the palmitoylation of a kinase, 
subsequently leading to the suppression of the activity of that kinase to prevent 
phosphorylation of p65 at Thr254 and disrupt p65 protein stability. Another 
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possible mechanism could involve FASN-mediated palmitoylation of a 
phosphatase, wherein palmitoylation results in increased phosphatase activity. 
 Neither the canonical kinase responsible for the phosphorylation of p65 at 
Thr254, nor any phosphatases responsible for removing phosphoryl groups from 
this site are known. Based upon the uncovered relationship between FASN and 
this p65 phosphorylation site, a logical place to start investigating a potential 
kinase or phosphatase in the context of breast cancer cells would be to first 
investigate those known to have a mechanistic relationship with FASN. 
 One particular kinase, PKC, has been linked to both FASN and p65. 
Specifically, one study has shown that, in response to FASN inhibition with the 
cerulenin derivative C93, the classical PKC isoform PKCa was activated and 
able to phosphorylate IkBa to result in its degradation and the subsequent 
activation of NF-kB (Lemmon et al. 2011). Further, multiple PKC isoforms have 
been found to be pamitoylated in proteomics studies, while the palmitoylation of 
PKCe has been verified in in vitro studies (Sanders et al. 2015; Dasgupta et al. 
2011). Interestingly, PKC is commonly known to translocate to the nucleus upon 
its activation. Given that it is believed the phosphorylated form of p65 is likely 
present in the nucleus, this suggests that activated PKC and p65 in this context 
would both be localized in the nucleus. As a result, it is possible FASN may affect 
the palmitoylation of a specific PKC isoform, thereby affecting its ability to 
phosphorylate p65 at Thr254. 
 Multiple studies have also linked FASN inhibition to the activation of AMP-
activated protein kinase (AMPK) (Landree et al. 2004; Zhou et al. 2007). Though 
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it has not been found in palmitoylome studies that AMPK can be palmitoylated, it 
is possible AMPK is involved in this process, as it has been shown that AMPK 
activation can increase NF-kB nuclear translocation and DNA binding activity (Liu 
et al. 2010). As a result, examining the potential relationship between FASN, NF-
kB/p65, and these kinases may lead to the determination of a more detailed 
mechanistic understanding of the ability of FASN to regulate NF-kB/p65. 
 In further consideration of the effects on total p65 level with the inhibition 
of palmitoylation activity shown in Appendix A, though 2-bromopalmitate is 
known to block palmitoylation of proteins, there is also evidence to suggest that it 
can behave similarly to palmitate in cells with respect to signaling processes 
(Resh 2006). For example, it has been shown that 2-bromopalmitate treatment 
can lead to gene expression changes through activation of peroxisome 
proliferator-activated receptors (PPARs), which are receptors for which palmitate 
is a common ligand (Brandes et al. 1995; Bastie et al. 2000). As a result, it must 
be considered that 2-bromopalmitate treatment in breast cancer cells could, in 
fact, be acting as a palmitate analog and could be affecting total p65 protein level 
not through a mechanism involving inhibition of palmitoylation, but rather through 
a cell signaling mechanism that is independent of palmitoylation activity and 
mirrors the effects of exogenous palmitate treatment. If this is the case, it is 
possible palmitate affects total p65 protein stability by a mechanism involving its 
other roles in cell signaling, such as modulation of membrane composition and 
lipid raft formation.  
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4.4. Relationship Between FASN and Kinase Activity 
 Due to previous research showing a relationship between phosphorylation 
of p65 and protein stability, I hypothesized that the effect of FASN on p65 protein 
stability may be the result of an effect exerted by FASN on phosphorylation. To 
initially investigate this hypothesis, a general kinase inhibitor known as 
staurosporine was utilized to determine if kinase activity may play a role in the 
effects of FASN on p65, and it was determined that staurosporine ablated the 
increases in total p65 protein level that are seen with FASN knockdown (Figure 
17).  
 While this initial experiment and conclusion provided insight for the 
direction of this thesis moving forward and was a logical starting point to 
investigate the relationship between FASN and p65 phosphorylation, the use of 
staurosporine as a general kinase inhibitor has caveats that must be explored. 
The primary mechanism of action of staurosporine is to bind to the ATP binding 
pocket of target kinases, thereby preventing the binding of ATP and disrupting 
kinase activity. However, staurosporine binds to kinases with very little selectivity 
as a consequence of the conserved nature of ATP binding pockets across the 
broad array of protein kinases. As a result, it may be difficult to determine 
whether the effects of staurosporine treatment on total p65 level speak to a 
causal relationship between FASN, activity of a specific kinase, and NF-kB/p65, 
or rather if the effects staurosporine exerts on total p65 level are more indirect, in 
that relatively global kinase inhibition could lead to effects on potential upstream 
kinases that may be responsible for regulating the cellular mechanisms and 
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molecular players within the signaling relationship that exists between FASN and 
NF-kB/p65.  
 Potential evidence for signaling consequences of inhibiting kinase activity 
on a relatively global level exist in that staurosporine is known to induce 
apoptosis in a variety of cell types. While many potential signaling mechanisms 
have been suggested for the role of staurosporine in triggering apoptosis, one 
mechanism commonly found is the activation of caspases, specifically caspase-3 
and caspase-9 (Chae et al. 2000; Malsy et al. 2019; Belmokhtar et al. 2001). 
Interestingly, one of these studies also found that staurosporine treatment 
actually led to an increase in NF-kB transcriptional activity (Chae et al. 2000). As 
staurosporine treatment resulted in a decrease in total p65 protein level, this 
suggests that the global kinase inhibition of staurosporine treatment may impact 
NF-kB signaling through a variety of different mechanisms. 
 
4.5. Relationship Between FASN, NF-kB, and TNF-a 
 The data in Figure 12 of this thesis has shown that FASN negatively 
regulates the expression of TNF-a, a canonical target gene of NF-kB signaling 
activation (Falvo et al. 2010; Liu et al. 2000). This finding was also consistent 
with previous research in the Zhang lab, which showed that FASN expression 
was negatively correlated with TNF-a expression, as well as TNF-a promoter 
activity (Liu et al. 2013). 
 While TNF-a is one of the genes commonly regulated by NF-kB, TNF-a is 
also one of the more common stimuli known to activate the NF-kB signaling 
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pathway, and, as a result, regulation of the expression of these two genes is 
often heavily intertwined (Aggarwal 2003). As a result, it would seem possible or 
even likely that, in a situation of reduced FASN expression or the presence of 
FASN inhibition, increased expression of NF-kB/p65 and increased NF-kB 
activity would promote increased expression and secretion of TNF-a, which could 
have the potential to create a positive feedback loop between TNF-a and NF-kB.  
 Literature evidence exists that would support the likelihood of this 
possibility. For instance, in acute myeloid leukemia (AML), it has been found that 
constitutive activity of NF-kB was promoted and maintained through continued 
secretion of TNF-a leading to a feedback loop of continuous autocrine signaling 
activation of NF-kB (Kagoya et al. 2012; Kagoya et al. 2014). This feedback loop 
activation has also been linked to other pathologies including rheumatoid arthritis 
and inflammatory bowel disease (Papa et al. 2004). As a result, it is worth 
consideration that increased FASN expression in breast cancer cells may result 
in decreased p65 protein stability, in part, in response to the disruption of a 
feedback loop between TNF-a and NF-kB that provides for continuous NF-kB 
activation and, consequently, increased p65 protein stability through a disruption 
in p65 proteasomal degradation. 
 
4.6. Relationship Between FASN, NF-kB, and PARP1 
 Previous research has determined a relationship between FASN, NF-kB, 
and PARP1, wherein FASN was able to upregulate PARP1 by suppressing the 
ability of NF-kB to inhibit PARP1 expression (Wu et al. 2016). As shown in 
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Figure 13, this relationship also holds true in breast cancer cells, wherein 
PARP1 is positively regulated by FASN expression as opposed to the negative 
regulation of NF-kB/p65 by FASN. As discussed earlier, previous research 
uncovered a composite binding site in the PARP1 promoter for p65 and another 
transcription factor, SP1 (Wu et al. 2016). It was also determined that, while 
overexpression of p65 suppressed PARP1 expression in pancreatic cancer cells, 
accompanying overexpression of SP1 in the presence of p65 suppressed the 
ability of p65 to negatively regulate PARP1. Specifically, when higher amounts of 
SP1 were transfected into pancreatic cancer cells, SP1 was able to overcome 
p65 to upregulate PARP1. Interestingly, this phenomenon is not unique to this 
mechanism as it has been found that NF-kB proteins can antagonize the binding 
of SP1 proteins to the P-selectin promoter (Hirano et al. 1998).  
 In the same study, exogenous palmitate treatment was able to upregulate 
SP1 protein level (Wu et al. 2016). Mechanistically, this finding is in concert with 
the finding in this thesis in Figure 8 that exogenous palmitate treatment was able 
to suppress p65 protein level. As palmitate appears to affect both SP1 and p65 
expression, it is possible that the unknown mechanisms through which FASN 
and palmitate impact SP1 and p65 are to some degree intertwined, as with the 
composite sites in the PARP1 promoter involved in SP1 and NF-kB regulation of 
PARP1 expression and activity. 
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4.7. Relationship Between FASN and Pin1 Expression 
 In this thesis, I have hypothesized that there is a relationship between NF-
kB/p65 and Pin1, wherein Pin1 assists in the stabilization of p65 protein in the 
absence of FASN expression or when FASN activity is inhibited. Specifically, I 
determined that both Pin1 knockdown and Pin1 pharmacological inhibition 
resulted in a decrease in total p65 protein level. In Figure 22, there was also 
found to be a slight increase in Pin1 protein level when FASN expression was 
knocked down in M3K doxorubicin resistant breast cancer cells. This finding is 
not wholly unexpected given that it follows the cellular mechanism determined in 
this thesis, wherein FASN expression is also negatively correlated with total p65 
expression.  
 However, the finding that FASN exhibits a negative relationship with Pin1 
expression in breast cancer cells is actually contradictory to a previous study, 
which determined that FASN exhibited a positive relationship with Pin1, wherein 
knockdown of Pin1 with siRNA and pharmacological inhibition of Pin1 reduced 
FASN protein level, and Pin1 pharmacological inhibition sensitized cells to 
HER2-targeted treatment with trastuzumab (Yun et al. 2014). It is worth noting, 
however, that this study was conducted solely utilizing HER2-positive breast 
cancer cell lines (SK-Br-3 and BT-474). This caveat is worth mentioning because 
previous research suggests the possibility that FASN may play a specific role in 
breast cancer cells that overexpress the HER2 receptor. To this end, previous 
research in the Zhang lab found no correlation between FASN expression level 
and sensitivity of MCF7 breast cancer cells—which express HER2 but at a low 
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level—to drugs that affect microtubules including paclitaxel and vinblastine (Liu et 
al. 2013). While other groups have shown that FASN inhibitors can sensitize 
breast cancer cells to microtubule inhibiting drugs, the ability of FASN inhibitors 
to sensitize cells was variable depending upon the cell line tested (Menendez et 
al. 2004; Menendez et al. 2004; Menendez et al. 2005). HER2 positive breast 
cancer cells, however, were consistently sensitized by multiple FASN inhibitors to 
multiple drugs targeted to microtubules in these studies. This suggests there may 
be some specific mechanism or interaction between FASN and HER2 in HER2-
overexpressing breast cancer cells that allows for inhibitors targeted to these two 
proteins to interact synergistically to kill cancer cells. Therefore, this potentially 
unique relationship between FASN and HER2 in HER2-overexpressing breast 
cancer cells may account for the contradictory relationship between FASN and 
Pin1 in our study compared with the findings of Yun et al.  
 
4.8. Cellular Consequences of the Relationship Between FASN and NF-kB 
 The characterized roles of NF-kB in cancer cells are variable in that NF-kB 
signaling activation, depending on the circumstance or the cell type, can have 
differing consequences on the cell. As described earlier in the introduction, the 
canonical role of NF-kB activation is typically oncogenic, characterized by the 
prevention of apoptosis, promotion of angiogenesis, and promotion of cellular 
proliferation. However, this phenomenon does not hold true in all settings, as NF-
kB signaling has also been found to promote cell death in certain instances 
(Kothny-Wilkes et al. 1998; Strozyk et al. 2006; Bian et al. 2001; Huang and 
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Johnson et al. 2000). As a result, it is potentially difficult to speculate on the 
downstream cellular consequences ensuing from the effects of the relationship 
between FASN and NF-kB/p65. For reference, Lemmon et al. found that, while 
FASN inhibition induced nuclear translocation and transcriptional activation of 
NF-kB in lung and prostate cancer cells, they also found that combined inhibition 
of FASN and NF-kB signaling resulted in increased cell killing compared to FASN 
inhibition alone (Lemmon et al. 2011). Further, it is worth noting that this 
phenomenon held true with the combination of FASN knockdown with siRNA and 
inhibition of NF-kB signaling, though this combined effect on cancer cell death 
was less pronounced than with pharmacological inhibition of FASN. The findings 
of this study suggest that, in this specific case, the activation of NF-kB in 
response to FASN inhibition or loss of FASN expression is, in fact, cytoprotective 
for cancer cells as blocking the activation resulted in more effective cell killing.  
 However, there are dissimilarities in the findings in this thesis relative to 
the findings of Lemmon et al. Specifically, with respect to the gene expression 
changes implicated in this mechanism as shown in Figure 13, FASN was shown 
to be a positive regulator of the expression of PARP1 in breast cancer cells, as 
opposed to the negative regulation of NF-kB/p65 by FASN. Dr. Zhang’s previous 
research has shown that p65 regulates PARP1 in this mechanism by 
suppressing PARP1 expression, whereas the high level of FASN expression 
present in breast and pancreatic cancer cells suppresses p65 to allow for the 
upregulation of PARP1 (Wu et al. 2016). As the functional effect of this 
suppression of p65 and upregulation of PARP1 was an increase in NHEJ DNA 
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repair activity and an increase in cancer cell survival to promote drug resistance 
to DNA-damaging agents, this finding suggests that NF-kB/p65 may be acting to 
promote cancer cell apoptosis in this mechanism. If this is the case, it would 
suggest that, rather than acting in its well-characterized role of increasing drug 
resistance by upregulating the expression of pro-survival genes, NF-kB activation 
downstream of decreased FASN expression or FASN inhibition may act to 
promote cell death by inhibiting PARP1 and possibly promoting cell death 
pathways such as the upregulation of Fas ligand (Kasibhatla et al. 1998). 
Interestingly, it has also been determined that Pin1 can also function in cell death 
mechanisms, wherein two studies have shown the ability of Pin1 to upregulate 
p53-mediated apoptosis (Sorrentino et al. 2013; Follis et al. 2015). In correlation 
with this role of Pin1, it has also been found that NF-kB activation promoted p53-
mediated cell death, whereas inhibition of NF-kB suppressed p53-mediated 
apoptosis, thereby suggesting a link between Pin1, NF-kB, and the promotion of 
cell death mechanisms (Ryan et al. 2000). However, further study is required to 
tease out the specific functional outcome of NF-kB/p65 in breast cancer cells in 
this mechanism.  
 
4.9. Relationship Between FASN and p65 Ser536 Phosphorylation 
 When attempting to determine a link between FASN, p65 protein stability, 
and phosphorylation of p65, I first investigated whether the site Ser536 was 
involved in the ability of FASN to regulate p65 protein stability. In Figure 20, I 
observed that, while decreased FASN expression led to a corresponding 
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increase in p65 Ser536 phosphorylation, similar to the increases in total p65 
protein level with FASN knockdown, loss of p65 Ser536 phosphorylation resulting 
from IKK inhibition did not subsequently affect total p65 level.  
 As a result of this finding, the increases in phosphorylation of p65 at 
Ser536 that are seen in response to FASN knockdown do not appear to be an 
upstream mechanism responsible for the effects FASN exerts on p65 protein 
stability. However, despite the conclusion that Ser536 phosphorylation is not 
involved in FASN regulation of p65 protein stability, FASN expression changes 
do appear to exhibit a relationship with Ser536 phosphorylation. It is possible that 
the increases in p65 Ser536 phosphorylation that are seen with FASN 
knockdown are merely a correlating effect on the ratio of phosphorylated p65 
protein to total p65 protein, wherein as the total protein level increases, the level 
of Ser536 phosphorylation increases proportionally.  
 It is worth noting, however, that Ser536 phosphorylation of p65 is heavily 
linked to NF-kB activation. With this in mind, the increase in Ser536 
phosphorylation seen with FASN knockdown aligns with the increase in NF-kB 
activity that is seen with FASN knockdown (Figure 11). In the context of the 
binding of Pin1 with p65 and the presence of phosphorylation of p65 at Thr254, 
structural data has indicated that both Thr254 phosphorylation and Pin1 binding 
occurs following the phosphorylation of IkBa and its subsequent release from 
p65 (Ryo et al. 2003). More specifically, this study showed that p65 is likely 
phosphorylated at Thr254 following nuclear translocation and transcriptional 
activation, as it was shown that Thr254 phosphorylated p65 did not interact with 
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IkBa and remained accumulated in the nucleus, indicating that this 
phosphorylation event prevented the ability of IkBa to export p65 from the 
nucleus and induce its proteasomal degradation (Ryo et al. 2003). On the 
contrary, it has been found that following stimulation, such as with TNF-a, 
Ser536 phosphorylation occurs relatively quickly while p65 and IkBa are still in 
complex in the cytoplasm (Mattioli et al. 2004). Further, it has also been found 
that only a very small percentage of Ser536 phosphorylated p65 is found in the 
nucleus, but is rather found predominantly in the perinuclear space, as it has 
been determined that p65 phosphorylation at Ser536 assists in controlling the 
kinetics of NF-kB nuclear import during activation (Mattioli et al. 2004; Moreno et 
al. 2010). As a result of this difference in the kinetics of these two 
phosphorylation events, it is possible that the increased Ser536 phosphorylation 
that is seen following FASN knockdown is a consequence of an initial increase in 
NF-kB activation that is seen with FASN knockdown, but that it is in fact the 
presence of Thr254 phosphorylation and activity of Pin1 in the nucleus 
downstream of initial NF-kB activation that predominates in regulating p65 
protein stability. If this is indeed the case, it would suggest that IKK mediated 
phosphorylation of p65 at Ser536 is not essential for maintaining p65 protein 
stability, and that constitutive nuclear accumulation of p65 could be maintained in 
the absence of this phosphorylation event. 
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4.10. Caveats and Limitations 
 There are caveats and limitations to the experimental methods utilized in 
this thesis. First, with regard to the cell lines utilized throughout the study 
pursued in this dissertation, there is somewhat a lack of consistency. For 
example, though MDA-MB-468 and MDA-MB-231 cells were utilized as 
supporting parental breast cancer cell lines for experimental data obtained for 
M3K cells, MDA-MB-436 cells with stable FASN overexpression were used as 
supporting cells for data obtained for M3K cells with stable FASN knockdown. 
Attempts were made to overexpress FASN in the MDA-MB-231 cells; however, 
these attempts were ultimately unsuccessful. Subsequently, as a result of the 
inability to overexpress FASN in the MDA-MB-231 cells, the MDA-MB-436 cells 
were chosen for stable FASN overexpression as a result of their low level of 
FASN expression and representative nature similar to MDA-MB-231 cells of the 
clinically relevant TNBCs. Regardless, it is worth acknowledging that a more 
appropriate choice for stable FASN overexpression would have been to use the 
MDA-MB-231 cells for a more direct comparison between studies using parental 
cell lines and studies using genetically-manipulated cells. 
 In addition, the results presented could have benefited from supporting 
studies using a second cell line with stable FASN knockdown. As the M3K 
doxorubicin resistant cells likely have many altered signaling pathways resulting 
from their stepwise drug resistance selection, it would likely be prudent for 
parallel experiments to be performed using the M3K/shFASN cells along with a 
second knockdown line, such as MDA-MB-231 cells with stable FASN shRNA 
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knockdown. This would provide the benefit of confirmation that the many altered 
signaling pathways in the M3K cells are not affecting results obtained in 
experiments with FASN knockdown. However, it is worth noting that previous 
attempts in our lab to produce stable FASN knockdown lines in parental cell lines 
have proved unsuccessful due to the reliance of the cancer cells on FASN for 
survival. As a result, it is possible that any studies utilizing FASN knockdown may 
require transient transfection. 
 In Figure 8, the experimental design involving the use of exogenous 
palmitate to affect total p65 levels has limitations. Specifically, in order to verify 
the role of palmitate in affecting total p65 level, a supporting control experiment 
will ultimately be necessary, wherein a free fatty acid quantification assay will 
need to be performed following the treatment of the M3K/shFASN and 
M3K/shScr cells with increasing concentrations of exogenous palmitate for 48 
hours in an effort to verify that the treatment vehicle for palmitate and treatment 
duration is sufficient to allow for palmitate to enter cells.  
 With additional regard to Figure 8, while a range of palmitate 
concentrations was initially used in this experiment, and it was determined that 
noticeable cell death did not occur until concentrations approached 100 µM, 
experimental evidence to verify the lack of an effect on cell viability at the 
experimental concentration (30 µM) was not provided in this thesis. As a result, 
this figure would benefit from the addition of a supporting experiment, wherein a 
cell viability assay could be performed using increasing concentrations of 
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exogenous palmitate to determine concentrations at which cell viability is 
compromised in the M3K/shFASN and M3K/shScr cells.  
 In some areas, experimental design in this thesis project could have also 
benefited from the use of additional controls. One such area that has application 
to multiple experiments within this thesis involves experiments wherein drug 
treatment or genetic manipulation was used to determine subsequent effects on 
total p65 following stable FASN shRNA knockdown. Examples of this type of 
experiment include Figure 22 and Figure 23, among others. In these 
experiments, an additional control could have been utilized, wherein the 
implicated genetic manipulation or drug treatment was also applied to the 
M3K/shScr cells in addition to the M3K/shFASN cells. This control would be 
useful in that it would allow for the determination of any potential direct effects of 
the genetic manipulation or drug treatment on total p65 as opposed to an effect 
that is seen in direct relation to the effects on total p65 that are mediated by 
FASN. 
 In Figures 18-21, TNF-a stimulation was utilized in an effort to induce 
detectable levels of phosphorylation of p65 at Ser536, and TNF-a was chosen to 
stimulate NF-kB in this context due to its previously characterized relationship 
with FASN. However, it must be noted that TNF-a is a promiscuous cytokine that 
can activate a variety of different signaling pathways involved in regulating both 
pro-survival and pro-apoptotic mechanisms (Wang and Lin 2008). As a result, 
utilizing TNF-a in these experiments creates a caveat, in that a variety of cell 
signaling pathways may be activated in response to TNF-a treatment, and these 
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signaling pathways may be affecting the relationship between FASN and p65. To 
attempt to alleviate potential concerns associated with TNF-a treatment, an 
additional control could be utilized in future experiments, wherein mirrored 
experiments are performed without TNF-a to provide evidence that TNF-a is 
simply magnifying effects on NF-kB downstream of FASN rather than inducing 
effects independent of and unrelated to the FASN-mediated mechanism.  
 
4.11. Future Directions 
 The data and conclusions presented in this thesis have expanded upon a 
previously developed hypothesis and cell signaling mechanism regarding the role 
played by the oncogenic enzyme FASN in breast cancer cells. Though a 
previously unknown mechanistic link between FASN and NF-kB/p65 in breast 
cancer cells was uncovered, wherein FASN negatively regulates p65 protein 
stability, further research and exploration is required to fully understand the 
scope of this signaling pathway involving FASN and NF-kB/p65.  
 As described in section 4.8, one of the most unclear areas of this 
mechanism involves the cellular consequences of the negative regulation of NF-
kB/p65 exerted by FASN. As a result, it is necessary to uncover what role NF-kB 
signaling plays in breast cancer cells in the context of this FASN-mediated 
mechanism. A logical place to begin with these investigations would be to utilize 
the functional endpoints of cell death and DNA repair that Dr. Zhang’s lab has 
previously explored with respect to this mechanism. To this end, overexpression 
of p65, as well as gene silencing or inhibition of NF-kB signaling could be used in 
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conjunction with FASN genetic manipulation and FASN inhibition to determine 
how manipulation of NF-kB signaling affects the ability of FASN to impact breast 
cancer cell death and NHEJ DNA repair activity. I hypothesize that NF-kB/p65 
signaling will negatively affect both breast cancer cell viability and NHEJ DNA 
repair activity due, in part, to the previously established effects of NF-kB/p65 in 
negatively regulating PARP1 expression and activity, which has been found to 
mediate the effects FASN exerts on DNA repair and cell survival (Wu et al. 
2016). If future research determines that NF-kB/p65 activation in the FASN 
signaling mechanism is acting in a pro-apoptotic manner, subsequent studies 
could investigate a potential ability for NF-kB/p65 to promote cell death 
mechanisms through Fas ligand signaling based on the characterized link 
between NF-kB and Fas ligand following DNA-damaging drug treatment 
(Kasibhatla et al. 1998). These experiments could also further be expanded to 
include treatment of cells with DNA-damaging drugs, including doxorubicin as an 
additional variable to specifically characterize the relationship between FASN, 
NF-kB, and resistance to DNA-damaging agents. 
 Another future aim within this mechanism that requires further exploration 
is the relationship between FASN, phosphorylation of p65 at Thr254, and Pin1. I 
was able to show in this thesis that Thr254 is important in FASN regulation of 
p65 protein stability, wherein it appears likely that FASN is able to suppress 
Thr254 phosphorylation of p65. I was also able to link FASN and p65 protein 
level to the expression and activity of Pin1. However, further research is required 
to establish a direct link between FASN, p65, and Pin1. To this end, future 
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research could expand the cycloheximide chase assay that was utilized in Figure 
21. Initially, a parallel experiment could be performed using the MDA-MB-468 
and MDA-MB-231 cells, wherein these cells would be transfected with either WT-
FLAG-p65 or FLAG-p65-T254A followed by 0-12 hour cycloheximide chase to 
confirm that mutation of Thr254 of p65 disrupts p65 protein stability in parental 
TNBC cell lines in addition to the observed effects in M3K cells with stable FASN 
shRNA knockdown. Subsequently, an experiment could be pursued, wherein the 
MDA-MB-468 and MDA-MB-231 cells would be transfected with WT-FLAG-p65 
in the presence or absence of siRNA targeting Pin1 or pharmacological inhibition 
of Pin1 prior to cycloheximide chase to determine the impact of the loss of Pin1 
expression and activity on p65 protein stability in breast cancer cells as a means 
of linking Pin1 to p65 protein stability. Experiments could also be performed to 
link Pin1 and Thr254 phosphorylation of p65, in that co-immunoprecipitation 
assays involving Pin1 and p65 could be pursued in the presence or absence of 
WT-FLAG-p65 or FLAG-p65-T254A transfection to determine if mutation of p65 
at Thr254 disrupts the interaction of p65 and Pin1.  
  Additionally, a clear caveat to the results summarized in this thesis is my 
inability to specifically determine that changes in FASN expression level can 
impact the level of p65 Thr254 phosphorylation. Multiple experimental methods 
were utilized in an effort to investigate this hypothesized causal relationship, 
including stimulating M3K/shFASN cells, along with their controls cells, as well as 
MDA-MB-436/FASN cells, along with their control cells, with TNF-a and 
performing Western blot analysis, wherein blots were probed with a p65 Thr254-
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specific antibody. Unfortunately, though several commercially available 
antibodies were tested, none effectively recognized this phosphorylation site so 
as to definitively measure the phosphorylation level at this site (data not shown). 
Further, I also attempted to utilize an antibody specific to phosphorylated 
threonine residues that are followed immediately by a proline residue (Cell 
Signaling). Using isogenic cell lines with FASN expression changes as described 
above, I performed immunoprecipitation to specifically pull down and isolate p65 
proteins from total protein lysate and subsequently performed Western blot for p-
Thr-Pro. However, while I was able to confirm that p65 was able to be pulled 
down and isolated from total protein lysate, the p-Thr-Pro antibody failed to 
specifically recognize the immunoprecipitated p65 (data not shown). Though 
these methods were unsuccessful in attempting to determine the relationship 
between FASN expression changes and Thr254 phosphorylation of p65, future 
research could utilize a mass spectrometry approach, wherein stable isotope 
labeling can be used within multiple cell pools (such as with an shRNA 
knockdown cell line and its scrambled shRNA control cell line) to subsequently 
be able to directly compare the intensity ratios of the MS peaks that are obtained 
for each cell pool as a means of direct quantitation of the phosphorylation level of 
p65 at the Thr254 site (Oda et al. 1999).  
 If utilization of this technique was able to determine a direct causal 
relationship between FASN and the negative regulation of Thr254 
phosphorylation level of p65 protein, an interesting research path would involve 
investigation into the molecular players involved in mediating changes in p65 
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Thr254 phosphorylation downstream of FASN expression. As discussed in 
section 4.3, PKC is a kinase that has been linked to both FASN and NF-kB/p65. 
As a result, exploration of this mechanism would benefit from the investigation 
into the potential relationship between FASN, PKC, and p65 Thr254 
phosphorylation. A simple way to investigate this would be to utilize gene 
silencing for specific PKC isoforms or pan-kinase inhibition for multiple PKC 
isoforms and measure p65 Thr254 phosphorylation levels in breast cancer cells 
in response to these manipulations. If pan-PKC inhibition did appear to affect p65 
Thr254 phosphorylation, as well as total p65 protein levels, the activity of specific 
PKC isoforms towards p65 could subsequently be investigated using an in vitro 
kinase assay. 
 Further, if PKC or another kinase was able to be implicated in the 
signaling mechanism between FASN and NF-kB/p65, it would subsequently be 
important to investigate the role of palmitate, downstream of FASN, in regulating 
the kinase responsible for regulation of p65 expression. To initially investigate the 
role of palmitate, an experiment similar to that shown in Figure 8 of this thesis 
could be employed, wherein exogenous palmitate treatment could be utilized to 
determine the effects on kinase activation and activity. If palmitate was able to be 
implicated using such an experiment, the acyl-biotin exchange assay could be 
utilized to determine if the responsible kinase is palmitoylated as a means for the 
effects exerted by FASN on that kinase. 
 Future research could also be devoted to further delineating the 
mechanism responsible for driving the degradation of p65 in the presence of high 
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FASN expression in breast cancer cells. While the data presented in this thesis 
shows that FASN induces p65 degradation through the proteasome following 
poly-ubiquitination of p65, the specific molecular players in this process remain 
unknown. As a result, it would be interesting to investigate which players in the 
ubiquitination and degradation cascade are involved in the process of FASN-
mediated p65 degradation.  
 Interestingly, while the first E3 ubiquitin ligase found to be responsible for 
mediating poly-ubiquitination of p65 was SOCS-1, many E3 ubiquitin ligases 
have been determined to mediate p65 poly-ubiquitination and subsequently play 
a role in driving p65 proteasomal degradation, including PDLIM2, PPARg, 
inhibitor of growth 4 (ING4), and human herpesvirus 8 (ORF73) (Ryo et al. 2003; 
Tanaka et al. 2007; Hou et al. 2012; Hou et al. 2014; Rodrigues et al. 2009). As a 
result, it would be interesting to investigate whether there is a specific E3 
ubiquitin ligase that conjugates ubiquitin to p65 in the context of FASN regulation 
of p65 in breast cancer cells. If this is the case, it would provide useful and 
significant insight into the level of context dependence of the activity of E3 
ubiquitin ligases and ubiquitination as a whole with respect to p65. This potential 
context dependence could be investigated quite simply by performing co-
immunoprecipitation experiments using p65 and the various E3 ubiquitin ligases 
known to have a relationship with p65, as well as by utilizing gene silencing of 
the E3 ubiquitin ligases to determine the effects on p65 protein expression, 
stability, and NF-kB activity in the presence of either knockdown or 
overexpression of FASN. 
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4.12. Conclusions and Significance of Findings 
 The findings presented in this thesis expand upon the mechanistic role of 
the oncogenic enzyme FASN in breast cancer, allowing for a previously 
undetermined role for FASN in suppressing NF-kB/p65 expression through a 
reduction in its protein stability via proteasomal degradation to be uncovered. 
Although FASN-targeted small molecule inhibitors have seen little clinical 
success to this point, FASN remains a well-studied target for the development of 
anti-cancer drugs and a key marker of tumor prognosis and clinical outcomes. As 
a result, the determination of the mechanism behind FASN activity in cancer cells 
presented here will be important for the field of breast cancer research, in that 
further delineating the key molecular players involved in the ability of FASN to 
regulate tumor growth, as well as resistance to anti-cancer agents, will allow for 
the potential determination of other targets that may be druggable both in concert 
with FASN-targeted drugs, as well as in conjunction with various 
chemotherapeutic agents. Exploring these avenues could allow for more clinical 
success in targeting the FASN pathway than has been achieved in the past with 
small molecule inhibitors of FASN. 
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APPENDIX 
Appendix A. The relationship between FASN, protein palmitoylation, and 
NF-kB/p65 is unclear. 
 In this thesis, it has been shown that FASN negatively regulates NF-
kB/p65 by disrupting its protein stability. Further, the effects on NF-kB/p65 
expression were shown to be reversed by reducing FASN expression, as well as 
inhibiting FASN activity. This mechanism also appears to specifically involve the 
phosphorylation site Thr254 of p65, as well as a p65 binding partner, Pin1. 
However, the upstream mechanism directly responsible for the ability of FASN to 
mediate these effects on p65 and p65 phosphorylation remains unclear.  
 As described earlier, FASN can impact cell signaling events through 
protein modification, specifically through a process known as protein 
palmitoylation, wherein a 16-carbon palmitate moiety is added to a cysteine 
residue. It has been shown in this thesis that exogenous treatment of breast 
cancer cells with the product of FASN catalysis, palmitate, results in a decrease 
in p65 protein level, indicating a specific role for palmitate in the mechanism. As 
a result, I hypothesized that protein palmitoylation may play a role in regulating 
the effects of FASN on p65, in that high levels of FASN expression may result in 
increased palmitoylation of certain proteins or p65 itself, which could then 
prevent p65 Thr254 phosphorylation and lead to disrupted p65 protein stability.  
 In order to investigate the potential relationship between protein 
palmitoylation and p65 in breast cancer cells, the palmitoylation inhibitor 2-
bromopalmitate (2-BP), which acts as a palmitate analog to block global protein 
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palmitoylation upon treatment, was utilized (Webb et al. 1999). As shown in 
Figure A-25, when M3K doxorubicin-resistant breast cancer cells were treated 
with 6 µM 2-BP for a period of 48 hours, total p65 protein level decreased 
compared to vehicle-treated cells. This result likely indicates that direct 
palmitoylation of p65 is not responsible for the effects of FASN on p65 protein 
stability, as, if this were indeed the case, high FASN level would be hypothesized 
to induce increased p65 palmitoylation to reduce p65 protein stability, which 
would suggest that inhibition of palmitoylation would result in an increase in total 
p65 level. However, this result does raise additional questions that are explored 
in section 4.3.   
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Figure A-25. The relationship between FASN, protein palmitoylation, and  
NF-kB/p65 is unclear. 
Western blot analysis of M3K drug-resistant breast cancer cells treated with 2-BP 
at 6 µM or vehicle (DMSO) for 48 hours. Membranes were probed for total p65 
for effects of 2-BP. Images were quantified using ImageJ. *p<0.05. Graph is 
representative of three independent experiments. Error bars represent standard 
deviation from the mean.  
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